ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
1,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
1,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
5,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
6,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
7,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
8,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
10,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
11,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
12,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
13,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
14,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
14,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
14,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
14,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
15,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
15,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
16,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
18,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
18,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
19,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
19,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
19,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
20,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
21,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
22,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
24,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
25,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
25,2,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
26,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
27,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
28,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
28,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
29,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
31,1,Colonic haematoma,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
31,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
31,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
31,4,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
32,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
32,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
33,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
34,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
36,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
36,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
36,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
37,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
37,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
38,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
38,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
39,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
41,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
41,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
41,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
42,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
43,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
44,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
44,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
45,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
45,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
46,1,Breast pain,Breast signs and symptoms,Breast disorders,Repro,N
46,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
46,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
47,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
48,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
48,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
50,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
50,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
50,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
50,4,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
51,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
51,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
52,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
53,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
54,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
55,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,2,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
55,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
55,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
55,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
56,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
56,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
56,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
57,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
57,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
58,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
59,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
60,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
60,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
61,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
62,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
63,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
63,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
63,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
63,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
64,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
64,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
65,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
65,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
66,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
67,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
67,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
68,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
68,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
69,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
69,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
70,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
71,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
71,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
72,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
72,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
73,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
73,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
74,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
75,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
75,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
75,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
76,1,Nail discolouration,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
76,2,Onycholysis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
77,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
77,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
78,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
78,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
79,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
79,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
80,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,2,Renal haemorrhage,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
81,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
81,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
82,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
82,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
83,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
83,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
83,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
84,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
84,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
84,3,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
85,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
86,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
87,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
88,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
89,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
89,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
90,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
91,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
91,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
91,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
92,1,Corneal oedema,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
92,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
92,3,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
92,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
92,5,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
93,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
93,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
94,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
94,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
95,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
95,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
95,3,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
96,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
97,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
97,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
98,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
98,2,Gingival swelling,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
98,3,Tooth abscess,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
99,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
99,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
99,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
100,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
101,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
101,2,Left ventricular failure,Left ventricular failures,Heart failures,Card,Y
102,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
102,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
103,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
103,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
104,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
105,1,Polymyositis,Muscle infections and inflammations,Muscle disorders,Musc,N
106,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
106,2,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
106,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
107,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
107,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
108,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
108,2,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
108,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
109,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
109,2,Intestinal infarction,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
110,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
110,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
111,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
111,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
112,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
113,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
113,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
114,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
114,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
114,3,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
115,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
115,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
116,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
116,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
116,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
117,1,Pulpless tooth,Dental pulp disorders,Dental and gingival conditions,Gastr,N
118,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
119,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
120,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
120,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
121,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
121,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,1,Bleeding varicose vein,Varicose veins NEC,Venous varices,Vasc,Y
123,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
123,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
124,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
125,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
125,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
125,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
126,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
127,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
127,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
128,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
129,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
129,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
130,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
131,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
132,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
133,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
134,1,Urine analysis abnormal,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
135,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
135,2,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
136,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
137,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
137,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
138,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
138,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
139,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
139,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
140,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
140,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
141,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
141,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
143,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
144,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
144,2,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
144,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
145,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
145,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
146,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
147,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
147,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
147,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
148,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
148,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
149,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
150,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
150,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
150,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
150,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
150,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
150,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
150,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
150,8,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
151,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
152,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
152,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
152,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
152,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
153,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
153,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
155,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
156,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
157,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,Y
158,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
158,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
158,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
159,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
159,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
160,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
161,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
161,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
162,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
162,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
162,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
163,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
163,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
164,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
164,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
165,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
165,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
166,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
166,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
166,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
167,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
168,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
168,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
169,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
169,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
170,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
170,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
171,1,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
172,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
172,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
172,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
173,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
173,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
173,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
173,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
174,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
174,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
175,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
175,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
176,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
176,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
176,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
176,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
177,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
177,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
177,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
177,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
178,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
178,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
179,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
179,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
180,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
180,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
181,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
181,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
182,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
182,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
183,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
184,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
185,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
186,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
186,2,Albuminuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
186,3,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
186,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
186,5,Henoch-Schonlein purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
186,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
187,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
187,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
188,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
189,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
190,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
190,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
190,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
191,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
191,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
193,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
193,2,Ovarian cyst,Ovarian and fallopian tube cysts and neoplasms,Ovarian and fallopian tube disorders,Repro,N
194,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
195,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
196,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
196,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
197,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
197,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
198,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
198,2,Granulocytopenia,Neutropenias,White blood cell disorders,Blood,N
198,3,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
198,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
199,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
199,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
199,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
199,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
200,1,Vulval ulceration,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
201,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
201,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
202,1,Albuminuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
202,2,Henoch-Schonlein purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
203,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
203,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
204,1,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
204,2,Tooth disorder,Dental disorders NEC,Dental and gingival conditions,Gastr,N
205,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
206,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
206,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
206,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
207,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
208,1,Cutaneous vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
209,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
210,1,Headache,Headaches NEC,Headaches,Nerv,N
211,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
212,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
212,2,Raynaud's phenomenon,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
213,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
214,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
215,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
216,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
216,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
217,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
217,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
218,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
218,2,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
218,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
219,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
220,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
221,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
222,1,Headache,Headaches NEC,Headaches,Nerv,N
223,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
223,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
224,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
224,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
224,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
225,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
226,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
227,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
227,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
228,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
228,2,Large intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
228,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
229,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
229,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
230,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
230,2,Glossitis,Tongue disorders,Tongue conditions,Gastr,N
231,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
231,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
233,1,Balanoposthitis,Penile and scrotal infections and inflammations,Male reproductive tract infections and inflammations,Repro,N
233,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
233,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
234,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
234,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
235,1,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
235,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
235,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
235,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
236,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
237,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
238,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
239,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
239,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
240,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
241,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
241,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
241,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
242,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
243,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
244,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
244,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
245,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
246,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
246,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
247,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
248,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
249,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
249,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
250,1,Uterine haemorrhage,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
251,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
252,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,Y
253,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
253,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
253,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
253,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
253,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
253,6,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
254,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
254,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
254,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
255,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
256,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
257,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
258,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
258,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
258,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
259,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
260,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
261,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
261,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
262,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
263,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
263,2,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
264,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
265,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
266,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
267,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
268,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
269,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
270,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
270,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
271,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
271,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
272,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
272,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
272,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
273,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
274,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
275,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
275,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
276,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
277,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
277,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
278,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
278,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
279,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
279,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
279,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
280,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
281,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
281,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
282,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
283,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
284,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
284,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
284,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
285,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
285,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
286,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
286,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
287,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
288,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
288,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
289,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
290,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
290,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
290,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
291,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
291,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
292,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
293,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
293,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
294,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
294,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
295,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
296,1,Nephritis,Nephritis NEC,Nephropathies,Renal,N
297,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
298,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
298,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
299,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
300,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
301,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
302,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
303,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
303,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
304,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
304,2,Prothrombin time abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
305,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
306,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
306,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
307,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
308,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
308,2,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
309,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
309,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
310,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
311,1,Headache,Headaches NEC,Headaches,Nerv,N
311,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
312,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
312,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
312,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
313,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
313,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
314,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
315,1,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
316,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
316,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
317,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
318,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
319,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
319,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
320,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
320,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
321,1,Acne,Acnes,Skin appendage conditions,Skin,N
322,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
322,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
323,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
323,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
324,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
324,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
325,1,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
326,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
327,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
328,1,Blepharitis,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
328,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
329,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
330,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
330,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
331,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
332,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
333,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
333,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
333,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
333,4,Sedation,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
333,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
334,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
334,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
335,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
336,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
336,2,Erosive duodenitis,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
336,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
336,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
337,1,Keratitis,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
338,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
338,2,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
339,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
340,1,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
341,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
342,1,Viral upper respiratory tract infection,Viral infections NEC,Viral infectious disorders,Infec,N
343,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
344,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
345,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
346,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
348,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
348,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
349,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
350,1,Intestinal ulcer,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
351,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
351,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
352,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
353,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
354,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
355,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
355,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
356,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
356,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
357,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
357,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
358,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
358,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
358,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
359,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
359,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
360,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
361,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
361,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
362,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
363,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
364,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
364,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
365,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
365,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
365,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
365,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
365,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
366,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
366,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
366,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
367,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
368,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
369,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
370,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
370,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
371,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
371,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
371,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
372,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
373,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
374,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
375,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
375,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
375,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
376,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
376,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
376,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
377,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
378,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
378,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
379,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
379,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
380,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
381,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
382,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
383,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
383,2,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
384,1,Congenital musculoskeletal disorder,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
385,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
385,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
385,3,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
386,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
387,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
388,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
388,2,Cytomegalovirus colitis,Cytomegaloviral infections,Viral infectious disorders,Infec,N
388,3,Diverticulum,Diverticula,Diverticular disorders,Gastr,N
388,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
388,5,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
388,6,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
389,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
390,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
391,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
392,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
392,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
393,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
394,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
394,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
395,1,Congenital musculoskeletal disorder,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
396,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
396,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
396,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
396,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
396,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
397,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
397,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
398,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
399,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
400,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
400,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
400,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
401,1,Semen analysis abnormal,Fertility analyses and other reproductive function procedures,Reproductive organ and breast investigations (excl hormone analyses),Inv,N
402,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
402,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
403,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
403,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
404,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
405,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
405,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
406,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
407,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
407,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
408,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
408,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
409,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
410,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
410,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
411,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
411,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
411,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
411,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
412,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
412,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
413,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
414,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
415,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
416,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
416,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
417,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
418,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
418,2,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
419,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
419,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
420,1,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
420,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
421,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
422,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
423,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
423,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
424,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
424,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
424,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
424,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
424,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
425,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
426,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
427,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
427,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
427,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
428,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
429,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
429,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
430,1,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
431,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
432,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
433,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
434,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
434,2,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
435,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
436,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
436,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
437,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
437,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
437,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
438,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
438,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
438,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
438,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
439,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
440,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
441,1,Congenital anomaly,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
442,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
443,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
443,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
444,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
444,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
445,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
445,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
446,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
446,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
447,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
447,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
447,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
448,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
449,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
450,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
450,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
451,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
451,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
452,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
452,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
453,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
454,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
455,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
456,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
457,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
458,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
458,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
459,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
460,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
460,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
461,1,Congenital musculoskeletal disorder,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
462,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
462,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
463,1,Gastrointestinal ulcer perforation,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
463,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
463,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
464,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
464,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
465,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
466,1,Libido decreased,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
467,1,Breast enlargement,Breast disorders NEC,Breast disorders,Repro,N
467,2,Breast pain,Breast signs and symptoms,Breast disorders,Repro,N
467,3,Breast tenderness,Breast signs and symptoms,Breast disorders,Repro,N
468,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
468,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
469,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
470,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
470,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
471,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
471,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
472,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
472,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
473,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
474,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
474,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
475,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
475,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
475,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
476,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
476,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
477,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
477,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
477,3,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
477,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
477,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
478,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
479,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
479,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
480,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
480,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
481,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
481,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
482,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
482,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
482,3,Renal colic,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
483,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
483,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
484,1,Cerebrovascular disorder,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,Y
485,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
486,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
487,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
488,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
488,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
489,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
489,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
490,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
491,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
492,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
492,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
493,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
493,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
493,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
494,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
495,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
496,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
497,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
497,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
498,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
499,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
499,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
500,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
501,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
501,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
502,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
502,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
503,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
504,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
505,1,Embolic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
505,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
505,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
506,1,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
507,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
508,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
508,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
508,3,Headache,Headaches NEC,Headaches,Nerv,N
508,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
509,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
510,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
511,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
511,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
512,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
513,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
514,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
515,1,Red blood cell sedimentation rate increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
516,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
517,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
518,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
519,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
520,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
521,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
522,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
522,2,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
523,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
524,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
525,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
525,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
526,1,Oesophageal ulcer haemorrhage,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
527,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
527,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
528,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
529,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
530,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
531,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
532,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
533,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
533,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
533,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
534,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
534,2,Congenital musculoskeletal disorder,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
535,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
535,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
536,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
536,2,Prothrombin time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
537,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
538,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
539,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
540,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
541,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
542,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
543,1,Haemorrhagic cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
544,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
544,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
545,1,Gravitational oedema,Oedema NEC,General system disorders NEC,Genrl,N
545,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
545,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
546,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
547,1,Spina bifida,Central nervous system disorders congenital NEC,Neurological disorders congenital,Cong,N
548,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
548,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
549,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
549,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
550,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
551,1,Henoch-Schonlein purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
552,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
552,2,Prothrombin time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
553,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
553,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
554,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
554,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
555,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
555,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
555,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
556,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
557,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
557,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
558,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
559,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
559,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
559,3,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
559,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
559,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
559,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
559,7,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
559,8,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
560,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
560,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
560,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
561,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
562,1,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
562,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
563,1,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
564,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
565,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
565,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
565,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
565,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
566,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
566,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
567,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
568,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,Y
569,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
570,1,Chorea,Choreiform movements,Movement disorders (incl parkinsonism),Nerv,N
571,1,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
572,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
572,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
573,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
574,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
575,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
575,2,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
576,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
577,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
577,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
578,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
579,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
579,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
579,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
579,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
579,5,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
580,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
581,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
581,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
582,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
583,1,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
584,1,Breast necrosis,Breast disorders NEC,Breast disorders,Repro,N
585,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
585,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
586,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
586,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
587,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
588,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
588,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
589,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
589,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
589,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
590,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
590,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
590,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
590,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
591,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,Y
591,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
591,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
591,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
592,1,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
592,2,Talipes,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
593,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
593,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
594,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
594,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
594,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
595,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
596,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
596,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
597,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
598,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
598,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
599,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
600,1,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
601,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
602,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
602,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
602,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
603,1,Abortion,Abortions not specified as induced or spontaneous,Abortions and stillbirth,Preg,N
603,2,Pseudolymphoma,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
604,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
605,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
605,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
605,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
606,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
606,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
607,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
607,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
608,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
609,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
609,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
609,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
609,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
609,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
610,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
610,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
611,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
611,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
612,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
612,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
613,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
614,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
615,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
616,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
617,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
618,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
619,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
620,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
621,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
622,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
623,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
623,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
624,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
624,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
625,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
626,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
626,2,Personality disorder,Personality disorders NEC,Personality disorders and disturbances in behaviour,Psych,N
627,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
628,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
628,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
628,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
629,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
630,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
631,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
631,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
632,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
632,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
633,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
634,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
634,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
635,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
636,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
637,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
637,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
638,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
639,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
640,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
641,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
641,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
642,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
642,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
643,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
643,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
644,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
645,1,Vasodilatation,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
646,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
647,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
648,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
649,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
650,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
651,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
652,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
653,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
653,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
654,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
655,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
656,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
657,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
658,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
659,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
660,1,Anal fissure,Anal and rectal disorders NEC,Anal and rectal conditions NEC,Gastr,N
661,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
662,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
663,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
664,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
665,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
666,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
667,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
668,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
669,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
670,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
671,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
672,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
673,1,Ear haemorrhage,Ear disorders NEC,Aural disorders NEC,Ear,N
673,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
673,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
674,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
675,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
676,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
677,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
678,1,Duodenitis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
678,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
678,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
678,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
679,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
680,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
681,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
681,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
682,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
683,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
683,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
683,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
684,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
684,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
684,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
685,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
686,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
687,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
687,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
688,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
688,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
689,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
689,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
690,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
690,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
691,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
691,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
692,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
693,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
694,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
694,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
695,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
695,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
696,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
697,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
697,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
698,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
698,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
699,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
699,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
700,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
700,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
701,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
702,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
702,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
703,1,Hypersensitivity vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
704,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
704,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
705,1,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
706,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
706,2,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
707,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
708,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
709,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
709,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
710,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
711,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
712,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
712,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
712,3,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
713,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
714,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
715,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
716,1,Depersonalisation/derealisation disorder,Dissociative states,Dissociative disorders,Psych,N
716,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
717,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
717,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
718,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
719,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
719,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
720,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
720,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
721,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
722,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
723,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
724,1,Multiple congenital abnormalities,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
725,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
726,1,Dermatomyositis,Connective tissue disorders,Epidermal and dermal conditions,Skin,N
727,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
727,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
727,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
728,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
728,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
729,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
730,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
731,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
732,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
732,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
733,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
733,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
734,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
734,2,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
735,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
735,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
735,3,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
735,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
736,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
736,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
737,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
737,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
738,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
738,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
739,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
739,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
740,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
740,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
741,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
741,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
741,3,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
742,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
742,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
742,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
742,4,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
742,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
743,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
744,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
745,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
746,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
746,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
746,3,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,Y
747,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
747,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
748,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
749,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
749,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
749,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
749,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
749,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
750,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
750,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
751,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
751,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
752,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
752,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
753,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
754,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
755,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
756,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
757,1,Clostridium difficile colitis,Clostridia infections,Bacterial infectious disorders,Infec,Y
757,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
758,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
758,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
759,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
760,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
760,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
760,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
760,4,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
761,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
762,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
762,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
763,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
764,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
764,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
764,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
765,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
766,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
766,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
767,1,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
767,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
767,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
768,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
768,2,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
769,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
769,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
770,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
770,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
771,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
771,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
772,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
773,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
773,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
774,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
775,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
775,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
776,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
776,2,Congestive hepatopathy,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
776,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
776,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
776,5,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
777,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
777,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
778,1,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,Y
779,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
779,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
780,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
780,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
781,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
781,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
782,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
783,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
784,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
785,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
785,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
785,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
785,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
786,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
786,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
786,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
786,4,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
787,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
788,1,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
789,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
790,1,Onycholysis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
791,1,Deafness,Hearing losses,Hearing disorders,Ear,N
791,2,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
792,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
793,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
793,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
794,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
795,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
796,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
797,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
797,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
798,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
799,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
800,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
801,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
802,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
803,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
803,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
804,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
805,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
806,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
806,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
807,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
808,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
809,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
809,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
810,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
810,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
811,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
812,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,Y
813,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
814,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
815,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
815,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
816,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
817,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
817,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
818,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
819,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
820,1,Small intestine carcinoma,Small intestinal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
821,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
821,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
821,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
822,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
822,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
823,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
823,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
824,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
824,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
825,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
825,2,Headache,Headaches NEC,Headaches,Nerv,N
826,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
826,2,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
827,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
828,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
828,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
829,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
829,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
830,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
831,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
832,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
833,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
834,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
835,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
836,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
836,2,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
836,3,Tongue blistering,Tongue signs and symptoms,Tongue conditions,Gastr,N
837,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
837,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
838,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
839,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
840,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
841,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
842,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
842,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
843,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
843,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
843,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
844,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
844,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
845,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
845,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
846,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
846,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
847,1,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
847,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
848,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
848,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
849,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
850,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
850,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
851,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
852,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
853,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
853,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
854,1,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
854,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
854,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
855,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
856,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
857,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
858,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
858,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
858,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
859,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
859,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
860,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
861,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
862,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
862,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
863,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
864,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
864,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
864,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
865,1,Congenital brain damage,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
866,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
866,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
867,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
868,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
869,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
870,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
871,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
872,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
872,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
872,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
873,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
874,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
875,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
875,2,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
875,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
876,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
876,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
876,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
877,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
878,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
878,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
879,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
880,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
881,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
881,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
882,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
882,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
883,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
884,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
885,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
885,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
886,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
887,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
888,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
889,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
889,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
890,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
891,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
892,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
893,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
894,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
895,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
895,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
896,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
896,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
897,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
898,1,Dysmorphism,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
898,2,Micrognathia,"Musculoskeletal and connective tissue disorders of face, neck and jaw congenital",Musculoskeletal and connective tissue disorders congenital,Cong,N
899,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
900,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
900,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
900,3,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
901,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
901,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
902,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
903,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
903,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
904,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
904,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
905,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
906,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
906,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
907,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
908,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
909,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
909,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
910,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
911,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
912,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
912,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
913,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
914,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
915,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
915,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
916,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
916,2,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
917,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
917,2,Ileus paralytic,Non-mechanical ileus,Gastrointestinal motility and defaecation conditions,Gastr,N
917,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
918,1,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
919,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
919,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
920,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
921,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
921,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
922,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
923,1,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
923,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
924,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
924,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
925,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
925,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
926,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
926,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
927,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
927,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
928,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
928,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
928,3,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
929,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
929,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
930,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
930,2,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
931,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
931,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
932,1,Coarctation of the aorta,Great vessel disorders congenital,Cardiac and vascular disorders congenital,Cong,N
933,1,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
933,2,Hypospadias,Male reproductive tract disorders congenital,Reproductive tract and breast disorders congenital,Cong,N
933,3,Pulmonary hypoplasia,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,N
934,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
934,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
935,1,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
936,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
937,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
937,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
937,3,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
938,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
939,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
939,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
939,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
939,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
940,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
940,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
941,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
941,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
942,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
942,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
943,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
944,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
944,2,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
944,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
945,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
946,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
947,1,Small intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
948,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
949,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
950,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
950,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
951,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
952,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
953,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
954,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
955,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
955,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
956,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
957,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
958,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
958,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
959,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
960,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
961,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
961,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
962,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
962,2,Myoclonus,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
962,3,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
962,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
962,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
963,1,Hirsutism,Hypertrichoses,Skin appendage conditions,Skin,N
964,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
965,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
965,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
966,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
966,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
967,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
967,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
968,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
969,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
970,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
970,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
971,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
972,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
973,1,Migraine,Migraine headaches,Headaches,Nerv,N
974,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
974,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
975,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
975,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
976,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
976,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
977,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
977,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
978,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
978,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
978,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
979,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
980,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
981,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
981,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
982,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
982,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
983,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
984,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
985,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
986,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
986,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
987,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
987,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
988,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
988,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
988,3,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
989,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
989,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
989,3,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
990,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
990,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
990,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
991,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
992,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
992,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
993,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
993,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
994,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
995,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
995,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
995,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
995,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
995,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
995,6,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
996,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
997,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
997,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
997,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
997,4,Prothrombin time abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
998,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
998,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
999,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1000,1,Dysmorphism,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
1001,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1002,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1002,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1003,1,Aneurysm,Aneurysms and dissections non-site specific,Aneurysms and artery dissections,Vasc,N
1003,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1003,3,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1003,4,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1003,5,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1004,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1004,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1005,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1005,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1006,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1007,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1007,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1007,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1008,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1008,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1009,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1009,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1010,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1010,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1010,3,Peptic ulcer haemorrhage,Peptic ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1011,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1012,1,Urethral disorder,Urethral disorders NEC,Urethral disorders (excl calculi),Renal,N
1013,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1013,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1014,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1014,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1014,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
1015,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1015,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1015,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1016,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1016,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1017,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1017,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1018,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1018,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1019,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1019,2,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1019,3,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1020,1,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
1021,1,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
1022,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1022,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1023,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1023,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1024,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1024,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1024,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
1024,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1024,5,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
1024,6,Systemic scleroderma,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
1025,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1025,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1026,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1027,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
1027,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1028,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1028,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1029,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1030,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1031,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
1032,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1032,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1032,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1032,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1032,5,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1033,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1033,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1033,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1034,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1035,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1035,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1035,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1035,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1036,1,Decreased interest,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
1036,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1036,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1036,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1037,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1038,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1038,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1039,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1039,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1039,3,Gastric polyps,Benign neoplasms gastrointestinal (excl oral cavity),Benign neoplasms gastrointestinal,Gastr,N
1039,4,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1040,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1041,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1042,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1043,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1044,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1044,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1044,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1045,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1045,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1046,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1046,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1046,3,Headache,Headaches NEC,Headaches,Nerv,N
1046,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
1047,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1047,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1047,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1047,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1048,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1048,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1049,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1049,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1050,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1050,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1050,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1050,4,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1050,5,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1051,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1051,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1051,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1052,1,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1052,2,Duodenal ulcer perforation,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1053,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1054,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1054,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1055,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1055,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1056,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1056,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1057,1,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1057,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1058,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1058,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1058,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1058,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1058,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1059,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1059,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1059,3,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
1060,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1060,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1061,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1061,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1062,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1062,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1063,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1064,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1064,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1065,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1066,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1067,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1067,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1068,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1068,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1069,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
1069,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1069,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1070,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1071,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1072,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1072,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1072,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1072,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1072,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1072,6,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1073,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1073,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1073,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1074,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1074,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1075,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1076,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1076,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1077,1,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1078,1,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1078,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1078,3,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1079,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1079,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1080,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1080,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1081,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1081,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1081,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1081,4,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1082,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1082,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1082,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1083,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1083,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1084,1,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
1084,2,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1085,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1086,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1087,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1088,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1088,2,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1089,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1090,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1090,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1091,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1091,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1092,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1092,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1093,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1094,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1094,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1094,3,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
1095,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1095,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1096,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1096,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1097,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1098,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,Y
1099,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1099,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1100,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1100,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1100,3,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1100,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1101,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1102,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1102,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1102,3,Vascular rupture,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1103,1,Hirsutism,Hypertrichoses,Skin appendage conditions,Skin,N
1104,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1105,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1106,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1107,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1107,2,Muscle rigidity,Muscle tone abnormalities,Muscle disorders,Musc,N
1107,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1107,4,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
1108,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1108,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1108,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1108,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1108,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1108,6,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1109,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1109,2,Libido decreased,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
1110,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1110,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1110,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1110,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1111,1,Acne,Acnes,Skin appendage conditions,Skin,N
1112,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1112,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1113,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1114,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1115,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
1116,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1116,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1117,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1117,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1118,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1118,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1119,1,Migraine,Migraine headaches,Headaches,Nerv,N
1120,1,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1121,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
1122,1,Multiple congenital abnormalities,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
1122,2,Neonatal seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1123,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1124,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1124,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1125,1,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1125,2,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1125,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1126,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1126,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1127,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1128,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1128,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1128,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1129,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1129,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1130,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1131,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1131,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1132,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1133,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1134,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
1134,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1134,3,Headache,Headaches NEC,Headaches,Nerv,N
1134,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1135,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1135,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1135,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1136,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1137,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1138,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1139,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1140,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1140,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1141,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1142,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1142,2,Pancreatic haemorrhage,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,Y
1143,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1144,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1144,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1145,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1146,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1146,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1147,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1147,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1147,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1147,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1147,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1147,6,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1147,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1147,8,Oliguria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1147,9,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1147,10,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1147,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1148,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1149,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1150,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1151,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1151,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1152,1,Anuria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1152,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
1152,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1152,4,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
1152,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1153,1,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1154,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
1154,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1154,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1155,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1156,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1157,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1157,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1158,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
1158,2,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1158,3,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1159,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1159,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1159,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1160,1,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1161,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,Y
1162,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1162,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1163,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1164,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1164,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1165,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1165,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1166,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1166,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1167,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1167,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1167,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1168,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1168,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1169,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1169,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1170,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1170,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1171,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1172,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1173,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1174,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1175,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1175,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
1176,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1177,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1177,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1178,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1178,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
1178,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1179,1,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
1180,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1181,1,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
1182,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1182,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1183,1,Cheilitis,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
1183,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1183,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1184,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1185,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1185,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1186,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1186,2,Duodenitis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1186,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1186,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1187,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1187,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1188,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1188,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1189,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1189,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1190,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1190,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1190,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1191,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
1191,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1192,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1193,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1193,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1194,1,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1195,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1196,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1197,1,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
1197,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1198,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1198,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1199,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1199,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1200,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1200,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1201,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1201,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1202,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1202,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1203,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1203,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1204,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
1204,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1204,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1205,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1206,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1207,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1207,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1208,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1209,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1209,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
1210,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1210,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1211,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1211,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1212,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1212,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1213,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1214,1,Gastritis haemorrhagic,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1214,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1215,1,Headache,Headaches NEC,Headaches,Nerv,N
1215,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1216,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1217,1,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1217,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1217,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1217,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1218,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,Y
1218,2,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1218,3,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1219,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
1219,2,Cerebrovascular disorder,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
1219,3,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1219,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1220,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1220,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
1220,3,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1220,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1220,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1221,1,Embolism arterial,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
1221,2,Intermittent claudication,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1221,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1221,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1222,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1223,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1223,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1224,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1224,2,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1224,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1225,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1225,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1226,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1226,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1226,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1227,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1227,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1228,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1228,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
1228,3,Hepatic haemorrhage,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
1229,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1229,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1230,1,Hangover,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1230,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1230,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1230,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1231,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1231,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1231,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1232,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1233,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1233,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1234,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1234,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1235,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1235,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1236,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1236,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1237,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1237,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1238,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1238,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1239,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1239,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1240,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1241,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1241,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1242,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1242,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1243,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1244,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1244,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1244,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1244,4,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1245,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1246,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1247,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1248,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1249,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1249,2,Gastroduodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1250,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1250,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1251,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1251,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1251,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1252,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1253,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1253,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1254,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1254,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1255,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1256,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1256,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1257,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1258,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1259,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1259,2,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1259,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1260,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1260,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1261,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1262,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1262,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1263,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1263,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1264,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1265,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1265,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1266,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1266,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1267,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1268,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1268,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
1268,3,Disinhibition,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
1268,4,Persecutory delusion,Delusional symptoms,Disturbances in thinking and perception,Psych,N
1269,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1270,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1271,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1271,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1272,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1273,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1273,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1274,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
1275,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1276,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1277,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1277,2,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
1278,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1278,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1279,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1280,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1280,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
1281,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1282,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1282,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1283,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1284,1,Foetal disorder,Foetal complications NEC,Foetal complications,Preg,N
1285,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1285,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1286,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1286,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1287,1,Breast pain,Breast signs and symptoms,Breast disorders,Repro,N
1287,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
1287,3,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1288,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1288,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1289,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1289,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1290,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1290,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1290,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1291,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1292,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1292,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1293,1,Mechanical urticaria,Urticarias,Angioedema and urticaria,Skin,N
1293,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1294,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1294,2,Prothrombin time abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1295,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1296,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
1297,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1298,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1298,2,Tongue oedema,Tongue signs and symptoms,Tongue conditions,Gastr,N
1299,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1299,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1300,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1300,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1301,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1302,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1302,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1302,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1302,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1302,5,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
1303,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1303,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1303,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
1303,4,Headache,Headaches NEC,Headaches,Nerv,N
1303,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1304,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1305,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1305,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1305,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1305,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1306,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1307,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1307,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1308,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
1308,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1308,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1309,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1309,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1309,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1310,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1311,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1311,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1311,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1311,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1312,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1312,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1313,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
1314,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1315,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1315,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1315,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1316,1,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1317,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1318,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1319,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1319,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1320,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1320,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1321,1,Breast necrosis,Breast disorders NEC,Breast disorders,Repro,N
1322,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1322,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1322,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1322,4,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1323,1,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1323,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1323,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1324,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1325,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1326,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1326,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1327,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1328,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1329,1,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1330,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1330,2,Headache,Headaches NEC,Headaches,Nerv,N
1330,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1331,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1331,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1332,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1332,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1333,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1334,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1334,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1335,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1335,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1336,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1336,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1337,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1338,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1338,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1338,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1339,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1339,2,Prothrombin level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1340,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1340,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1341,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1341,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1342,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1342,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1342,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1343,1,Aortic dissection,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
1343,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1344,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1344,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1345,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1345,2,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1345,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1346,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1347,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1347,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1347,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1347,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1348,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1349,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1349,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1349,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1349,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1350,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1350,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1350,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1351,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1351,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1352,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1353,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1354,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1355,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1356,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1356,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1357,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1358,1,Hyperkeratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
1359,1,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,Y
1360,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1360,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1361,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1361,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1362,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1362,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1363,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
1364,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
1365,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
1366,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1366,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1367,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1367,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1368,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1369,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1369,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1370,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1371,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1371,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1372,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1372,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1373,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1373,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1373,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1374,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1375,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1375,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1376,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1377,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1377,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1378,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1378,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1379,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1379,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1380,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1380,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1381,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1381,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1381,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1382,1,Bronchitis viral,Viral infections NEC,Viral infectious disorders,Infec,N
1382,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1382,3,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
1382,4,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
1382,5,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
1383,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
1383,2,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
1383,3,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
1384,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1384,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1384,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1385,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1385,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1385,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1386,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1387,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1388,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1388,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1389,1,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
1389,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1389,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1389,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1390,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1391,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1391,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
1391,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1391,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1392,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1392,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1393,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1394,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1394,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1395,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1395,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1396,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1397,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
1397,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1397,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1397,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1398,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1398,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1398,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1399,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1399,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1399,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1400,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1400,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1401,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1401,2,Lip haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
1402,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1402,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1402,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1403,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1403,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1403,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1404,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1404,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1405,1,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
1405,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1405,3,Helicobacter infection,Helicobacter infections,Bacterial infectious disorders,Infec,N
1406,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1406,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1407,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1407,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1408,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1408,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1409,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1409,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1410,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1410,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1410,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1411,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1412,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1413,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1413,2,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1413,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1414,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1415,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1416,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1416,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1417,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1417,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1417,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1418,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1418,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1419,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1419,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1420,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1420,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1421,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1421,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1422,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1422,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1423,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1423,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1424,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1425,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1426,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1426,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1427,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1427,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1428,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1428,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1428,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1429,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1429,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1430,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1430,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1431,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1432,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1433,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1433,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1433,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1434,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1434,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1434,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1434,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1435,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1435,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1436,1,Feeling jittery,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1436,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1437,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1437,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1437,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1438,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1439,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1439,2,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,Y
1440,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1441,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1442,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1443,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
1444,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1444,2,Periorbital haematoma,Eye injuries NEC,Injuries NEC,Inj&P,N
1444,3,Traumatic haematoma,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1445,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1445,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1446,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1446,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1446,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1446,4,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1447,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1447,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1448,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1449,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1450,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1450,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1451,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1451,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1452,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1452,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1453,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1453,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1454,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1454,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1454,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
1455,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1455,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1456,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1456,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1457,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1457,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1457,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1458,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1458,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1459,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1460,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1460,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1460,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1460,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1461,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1462,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1462,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1462,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1463,1,Parosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
1464,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1465,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1465,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1465,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1466,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1466,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1467,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1467,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1468,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
1468,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1468,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1468,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1469,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
1470,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1471,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1472,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1472,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1472,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1473,1,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1473,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1474,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1474,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1474,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1475,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1475,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1476,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1476,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1476,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1477,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1477,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1477,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1478,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1479,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1480,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1481,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1481,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1482,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1482,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1482,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1483,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1483,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1484,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1485,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1486,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1486,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1487,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1487,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1488,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1489,1,Deafness unilateral,Hearing losses,Hearing disorders,Ear,N
1490,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1490,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1490,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1490,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1491,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1492,1,Diastolic hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1492,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1492,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1493,1,Coagulation time abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1494,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1494,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1494,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1494,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1495,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1495,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1495,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1496,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1497,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1497,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1498,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1498,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1499,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1499,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1500,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1500,2,Axonal neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
1500,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1500,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1500,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1500,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1500,7,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
1500,8,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1500,9,Hyporeflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
1500,10,Hyporeflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
1500,11,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1500,12,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1500,13,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1500,14,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1501,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1501,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1502,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1502,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1502,3,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1502,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1503,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1503,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1504,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1504,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1504,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1505,1,Hypotonia,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
1506,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1506,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1506,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
1507,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1508,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1508,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1509,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1509,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1510,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1510,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
1511,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1511,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1512,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1512,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1512,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1512,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1513,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
1513,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1514,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1514,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1515,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1515,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1516,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1516,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1517,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1517,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1518,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1518,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1518,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1519,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1519,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1520,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1520,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1520,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1521,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1521,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1522,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1522,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1523,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1523,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1524,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1524,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1525,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1525,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1525,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1525,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1526,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1526,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1527,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1527,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1528,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1529,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1529,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1530,1,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1531,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1531,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1531,3,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1531,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
1532,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1532,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
1532,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1532,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1532,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1532,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
1533,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1533,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1533,3,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1533,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1533,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1534,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1534,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1535,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1535,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1536,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1536,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1536,3,Pulmonary alveolar haemorrhage,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1537,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1538,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1538,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1539,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1539,2,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1539,3,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
1540,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1541,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1542,1,Traumatic haematoma,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1543,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1543,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1543,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1543,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1544,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1545,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1545,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1545,3,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1545,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1545,5,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
1545,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1546,1,Gastric polyps,Benign neoplasms gastrointestinal (excl oral cavity),Benign neoplasms gastrointestinal,Gastr,N
1546,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1546,3,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1546,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1546,5,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1547,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1548,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1548,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1549,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1550,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1551,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1551,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1552,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1552,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1553,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1553,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1554,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1554,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1555,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1555,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1556,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1556,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1556,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1556,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1557,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1557,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1557,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1558,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1558,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1559,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1559,2,Drug level changed,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1559,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1559,4,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1560,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1560,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1560,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1561,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
1561,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1561,3,Headache,Headaches NEC,Headaches,Nerv,N
1561,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1561,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1561,6,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1561,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1562,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1562,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1563,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
1564,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1565,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1566,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1566,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1567,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
1568,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1568,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1569,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1569,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1569,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1569,4,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
1570,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1570,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1571,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1571,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1572,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1572,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1573,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1573,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1573,3,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
1574,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1574,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1575,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1575,2,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1576,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1577,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1578,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1579,1,Hypotonia,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
1579,2,Miosis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
1579,3,Pupillary light reflex tests abnormal,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1579,4,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
1579,5,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1580,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1580,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1581,1,Anorgasmia,Orgasmic disorders and disturbances,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
1582,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1582,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1583,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1583,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1584,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1584,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
1584,3,Perineal haematoma,Reproductive tract disorders NEC (excl neoplasms),Reproductive tract disorders NEC,Repro,N
1585,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1586,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1586,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1587,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1587,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1587,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1588,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1588,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1589,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1590,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1590,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1590,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1590,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1590,5,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1591,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1591,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1592,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1593,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1593,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1594,1,Sticky skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1594,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1595,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1595,2,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1595,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1595,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1596,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1596,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1596,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1597,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1598,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1598,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1599,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1599,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1600,1,Cardio-respiratory arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1600,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1600,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1600,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1601,1,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1601,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1601,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1602,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1603,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1604,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1604,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1605,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1606,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1606,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1606,3,Hepatic haematoma,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
1606,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1607,1,Kyphoscoliosis,Spine and neck deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
1608,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1608,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1609,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1610,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1610,2,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
1611,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1611,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1611,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1612,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1612,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1613,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1614,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1614,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1614,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1615,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1615,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1616,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1616,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1617,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1617,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1618,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1619,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1620,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1620,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1621,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1621,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1621,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1622,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,Y
1623,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1624,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1624,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1625,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1626,1,Headache,Headaches NEC,Headaches,Nerv,N
1626,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1626,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1626,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1626,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1627,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1627,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1628,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1629,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1629,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1630,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1630,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1631,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1631,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1632,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1633,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1634,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1634,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1634,3,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1634,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1634,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1635,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1635,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1636,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1637,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1637,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1638,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1638,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
1639,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1639,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1640,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1640,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1641,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1641,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1642,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1642,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1643,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1643,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1643,3,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1643,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1644,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1644,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1645,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1645,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1646,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1647,1,Craniocerebral injury,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1647,2,Ear haemorrhage,Ear disorders NEC,Aural disorders NEC,Ear,N
1647,3,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1647,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1647,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1648,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1649,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1649,2,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1649,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1650,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1650,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1651,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1651,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1652,1,Diabetes insipidus,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
1652,2,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
1652,3,Mydriasis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
1652,4,Pupil fixed,Pupil disorders,Ocular neuromuscular disorders,Eye,N
1652,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1653,1,Alcohol poisoning,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1653,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1653,3,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1653,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1653,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1654,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1654,2,Prostatitis,Prostate and seminal vesicles infections and inflammations,Male reproductive tract infections and inflammations,Repro,N
1655,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1655,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1656,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1656,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1656,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1657,1,Duodenitis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1657,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1657,3,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1657,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1658,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1658,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1658,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1658,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1659,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1659,2,Mydriasis,Pupil disorders,Ocular neuromuscular disorders,Eye,N
1659,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1659,4,Sedation,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1659,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1660,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1661,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1661,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1661,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1662,1,Fat necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
1663,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1664,1,Headache,Headaches NEC,Headaches,Nerv,N
1665,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1665,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1665,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1665,4,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1666,1,Headache,Headaches NEC,Headaches,Nerv,N
1666,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1667,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1668,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1668,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1669,1,Purple glove syndrome,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1669,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1670,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1670,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1671,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1671,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1671,3,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1671,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1671,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1671,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1671,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1671,8,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1672,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1673,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1674,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1674,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1674,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1674,4,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,Y
1675,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1675,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1675,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1676,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1676,2,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1676,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1676,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1677,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1677,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1678,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1678,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1679,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1679,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1680,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1681,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1682,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1682,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1683,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1683,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1683,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1684,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1684,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1685,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1685,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1686,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1686,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1687,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1687,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1688,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1689,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1689,2,Hepatic haemorrhage,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
1690,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1690,2,Oesophagitis ulcerative,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1691,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1692,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1692,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1693,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1693,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1693,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1694,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1694,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1695,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1695,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1696,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1696,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1696,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1697,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1697,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1698,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1698,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1698,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1699,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1699,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1699,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1700,1,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1701,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1702,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1703,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1704,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1704,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1704,3,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1705,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1705,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1706,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
1706,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1707,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1707,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1708,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
1709,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1709,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1710,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1710,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1710,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1711,1,Foetal disorder,Foetal complications NEC,Foetal complications,Preg,N
1712,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1712,2,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
1713,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1713,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1714,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1714,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1714,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1715,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1716,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1716,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1717,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1717,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1718,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1718,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1719,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1719,2,International normalised ratio,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1720,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1720,2,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1720,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1721,1,Anticoagulant therapy,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
1721,2,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
1722,1,Breast disorder,Breast disorders NEC,Breast disorders,Repro,N
1722,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1723,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
1723,2,Congenital musculoskeletal disorder,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
1723,3,Heart disease congenital,Cardiac disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
1724,1,Intestinal infarction,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
1725,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1725,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1726,1,Carpal tunnel syndrome,Mononeuropathies,Peripheral neuropathies,Nerv,N
1727,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1727,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1728,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1728,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1729,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1729,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1730,1,Duodenitis haemorrhagic,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1730,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1730,3,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1731,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1732,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
1733,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1734,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1734,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1735,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1735,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1736,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1736,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1737,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1737,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
1738,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,Y
1739,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1740,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1741,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1741,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1741,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1741,4,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1741,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1741,6,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1741,7,Suprapubic pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1741,8,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
1742,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1742,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1743,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1743,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1744,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1744,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1744,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1745,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1745,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1745,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1746,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1746,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1747,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1747,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1748,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1749,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1749,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1750,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1750,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1751,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1751,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1752,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1753,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1753,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1754,1,Headache,Headaches NEC,Headaches,Nerv,N
1755,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1755,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1756,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1756,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1756,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1757,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1758,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1758,2,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1759,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1760,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1760,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1761,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1761,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1762,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1762,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1762,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1762,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1763,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
1764,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1764,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1765,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1766,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1767,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
1768,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1768,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1768,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1768,4,Urine abnormality,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1769,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1770,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1770,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1771,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1772,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1772,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1773,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1773,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1774,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1774,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1775,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1775,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1776,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1777,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1777,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1777,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1778,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1778,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1778,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1778,4,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
1778,5,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1779,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1779,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1780,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1780,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1781,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1781,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1781,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1782,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1783,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1784,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1784,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1785,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1786,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1787,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1787,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1788,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1789,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1789,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1790,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1790,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1791,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1791,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
1792,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1793,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1793,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1793,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1794,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1794,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1795,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1796,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1796,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1796,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1797,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1797,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1798,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1798,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1798,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1799,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1799,2,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1799,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1799,4,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1799,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1799,6,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
1800,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1801,1,Pelvic haemorrhage,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,Y
1802,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1803,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1803,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1804,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1804,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1804,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1804,4,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
1804,5,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
1805,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1805,2,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1805,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
1805,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1806,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1806,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1807,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1807,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1808,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1808,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1809,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1809,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1810,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1810,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1811,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1811,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1812,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1812,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,Y
1812,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1812,4,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1813,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1813,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1813,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1813,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1814,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1814,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1814,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1814,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1815,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1815,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1816,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1816,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1816,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1817,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1818,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1818,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1818,3,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
1819,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1819,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1819,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1820,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1821,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1822,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1822,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1823,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1823,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1824,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1824,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1825,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1825,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1825,3,Post procedural haematoma,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
1825,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1825,5,Wound complication,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1826,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1826,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1827,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1827,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1828,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1828,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1828,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
1829,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1829,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1830,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1831,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1831,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1832,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1832,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1832,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1832,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1833,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1833,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1834,1,Cerebral ischaemia,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1834,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1834,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1835,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1835,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1836,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1836,2,Headache,Headaches NEC,Headaches,Nerv,N
1836,3,Polydipsia,Fluid intake increased,Electrolyte and fluid balance conditions,Metab,N
1836,4,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
1837,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1838,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1838,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1838,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1838,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1839,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1839,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1840,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1840,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1841,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1842,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1842,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1843,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1843,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1843,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1844,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1844,2,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
1844,3,Jaundice acholuric,Haemolyses NEC,Haemolyses and related conditions,Blood,N
1845,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1846,1,Traumatic haematoma,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1847,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1848,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1848,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1849,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1850,1,Carpal tunnel syndrome,Mononeuropathies,Peripheral neuropathies,Nerv,N
1850,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1850,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1851,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1851,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1852,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1852,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1852,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1852,4,Pneumonia aspiration,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
1852,5,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
1852,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1853,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1853,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1854,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1854,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1854,3,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1855,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
1856,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1856,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1857,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1857,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1857,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1858,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1859,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1859,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1860,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1861,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1862,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1862,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1863,1,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1864,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1864,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1865,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1865,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
1865,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1865,4,Migraine,Migraine headaches,Headaches,Nerv,N
1865,5,Visual field defect,Visual field disorders,Vision disorders,Eye,N
1866,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1866,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1867,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1868,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1869,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1869,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1870,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1870,2,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1870,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
1870,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1871,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1871,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1871,3,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1871,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1872,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1873,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1873,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
1873,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
1873,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
1874,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1874,2,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1874,3,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
1875,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1875,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1875,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1875,4,Vitamin K decreased,Vitamin analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
1876,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1876,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1877,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1877,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1878,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1878,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1879,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1879,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1879,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1879,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1879,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1879,6,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1880,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1880,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1881,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1881,2,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
1882,1,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1883,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1883,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1884,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1885,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1885,2,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1885,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1885,4,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1885,5,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1886,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1886,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1887,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1887,2,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1887,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1888,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1888,2,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1889,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1890,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1890,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1891,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1891,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1892,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1893,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1893,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1894,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
1894,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
1894,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1894,4,Mesenteric artery thrombosis,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,Y
1894,5,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1895,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1896,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1896,2,Duodenitis haemorrhagic,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1897,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1897,2,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
1897,3,Slow response to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1898,1,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1898,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1898,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
1899,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1900,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1900,2,Tongue haemorrhage,Tongue disorders,Tongue conditions,Gastr,N
1901,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1901,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1902,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1902,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1902,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1903,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1903,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1904,1,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1904,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1905,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1905,2,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1905,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1905,4,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1906,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1906,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1906,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1907,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
1908,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1908,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1908,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1908,4,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
1908,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1908,6,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,Y
1909,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1909,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1909,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1909,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1910,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1911,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
1912,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1912,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1913,1,Anticoagulation drug level,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1913,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1913,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1913,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1914,1,Conjunctival disorder,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
1914,2,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
1914,3,Corneal disorder,Corneal disorders NEC,Eye disorders NEC,Eye,N
1914,4,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
1914,5,Eye discharge,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
1914,6,Lagophthalmos,"Lid, lash and lacrimal structural disorders","Anterior eye structural change, deposit and degeneration",Eye,N
1915,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1916,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1916,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1917,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1917,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1918,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1918,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1918,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1918,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1919,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1919,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1919,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1919,4,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1919,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1919,6,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1919,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1919,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1919,9,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1919,10,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1919,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1919,12,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1919,13,Ureteric obstruction,Ureteric disorders NEC,Ureteric disorders,Renal,N
1919,14,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1920,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1920,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1921,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
1922,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1922,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1923,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1923,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1923,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1923,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1924,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1924,2,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
1924,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1925,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1926,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1926,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1927,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1928,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1928,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1928,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1928,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1928,5,Mesenteric artery thrombosis,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,Y
1928,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1928,7,Pulse abnormal,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1928,8,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1928,9,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1929,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1929,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1930,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1930,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1930,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
1931,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1932,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1932,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1933,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1933,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1933,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1933,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1933,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1934,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1934,2,Oesophageal ulcer haemorrhage,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1935,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1936,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1936,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1937,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1937,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1938,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
1939,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1940,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1940,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1941,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1941,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1942,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1942,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1943,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1943,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1943,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
1944,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1945,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1945,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1945,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1945,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1945,5,Headache,Headaches NEC,Headaches,Nerv,N
1945,6,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1945,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1945,8,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1945,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1946,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1946,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1947,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1947,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1948,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1948,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1949,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1949,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1950,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1950,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
1951,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1951,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
1952,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1952,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
1952,3,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
1953,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1953,2,Pituitary haemorrhage,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
1954,1,Electrocardiogram ST segment elevation,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1954,2,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1954,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1955,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
1955,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1955,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1955,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1955,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1955,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
1955,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1955,8,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1955,9,Procedural pain,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
1955,10,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1955,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1956,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1956,2,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1957,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1957,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1957,3,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1958,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1958,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1958,3,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1958,4,Anuria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1958,5,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1958,6,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1958,7,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1958,8,Cardioactive drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
1958,9,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
1958,10,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
1958,11,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1958,12,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1958,13,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1958,14,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1958,15,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1958,16,Gastrointestinal sounds abnormal,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
1958,17,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1958,18,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1958,19,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
1958,20,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
1958,21,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1958,22,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1958,23,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
1958,24,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
1958,25,Pulse absent,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1958,26,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1958,27,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1958,28,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1958,29,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1959,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1960,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1960,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1961,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1961,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1961,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1961,4,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1962,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1962,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1963,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1963,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1963,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1964,1,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1964,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1965,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1965,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1965,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1965,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1965,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1966,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1966,2,Hydronephrosis,Renal obstructive disorders,Renal disorders (excl nephropathies),Renal,N
1966,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1966,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1967,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1967,2,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1968,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1968,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1969,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1970,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1970,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1970,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1970,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1971,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1971,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1971,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1972,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1972,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
1972,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1973,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1973,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1974,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1975,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1975,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1975,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1975,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1975,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1975,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1975,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1976,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1976,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1977,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1977,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1977,3,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1978,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1978,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
1978,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1978,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1979,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1979,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1980,1,Headache,Headaches NEC,Headaches,Nerv,N
1981,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1981,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1982,1,Headache,Headaches NEC,Headaches,Nerv,N
1983,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
1983,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1983,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1983,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1984,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1984,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1985,1,Acne,Acnes,Skin appendage conditions,Skin,N
1985,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1985,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1985,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1985,5,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1986,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1986,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
1986,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1986,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1987,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
1987,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1987,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1987,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1987,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1987,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1987,7,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1988,1,Hypothermia,Body temperature altered,Body temperature conditions,Genrl,N
1988,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1988,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
1988,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1989,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
1990,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1991,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1992,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1993,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1993,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1994,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1994,2,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1994,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1994,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1995,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1995,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
1995,3,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1996,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1996,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1997,1,Axillary vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
1997,2,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
1997,3,Heparin-induced thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1997,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1997,5,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1997,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
1998,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
1998,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1998,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1999,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1999,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2000,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2000,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2000,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2000,4,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
2000,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2000,6,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
2000,7,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2000,8,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
2001,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2002,1,Genital haemorrhage,Reproductive tract disorders NEC (excl neoplasms),Reproductive tract disorders NEC,Repro,N
2002,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2002,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2003,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2003,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2004,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2004,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2005,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2005,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2006,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2006,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2006,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2006,4,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2006,5,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
2006,6,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2006,7,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
2006,8,Macrocytosis,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
2006,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2006,10,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2006,11,Oliguria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2006,12,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2006,13,Polychromasia,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
2006,14,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2006,15,Red blood cell abnormality,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
2006,16,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
2006,17,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2006,18,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2007,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2008,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2009,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2009,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2009,3,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2010,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2010,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2010,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2011,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2011,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2011,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2011,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2011,5,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
2011,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2012,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2012,2,Drug level fluctuating,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2013,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2013,2,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2013,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2014,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2014,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2015,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2015,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2015,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2015,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2016,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
2016,2,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2016,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2016,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
2017,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2017,2,Pelvic fracture,Pelvic fractures and dislocations,Bone and joint injuries,Inj&P,N
2017,3,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2017,4,Vascular injury,Cardiovascular injuries,Injuries NEC,Inj&P,N
2018,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2019,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2019,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2020,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2021,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2021,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2022,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2022,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2023,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2023,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2024,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2025,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
2025,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2026,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2026,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2027,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2027,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
2027,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2028,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
2028,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2028,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2028,4,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
2029,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2029,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2030,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2030,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2031,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2031,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2031,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
2032,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2032,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2032,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2033,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2033,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2034,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2034,2,Haemorrhage subcutaneous,Skin haemorrhages,Skin vascular abnormalities,Skin,N
2034,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2035,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2035,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2035,3,Headache,Headaches NEC,Headaches,Nerv,N
2035,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2035,5,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2035,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2036,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2036,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2037,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2037,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2038,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2038,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2039,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2040,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2040,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2041,1,Anhedonia,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
2041,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2041,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2041,4,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2041,5,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
2041,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2042,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2042,2,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
2043,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2043,2,Gastric varices haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2044,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2044,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2044,3,Headache,Headaches NEC,Headaches,Nerv,N
2044,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
2044,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2044,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2045,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2046,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2047,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2047,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2048,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2048,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2049,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2049,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2050,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2050,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2051,1,Breast haemorrhage,Breast signs and symptoms,Breast disorders,Repro,N
2051,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2052,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2052,2,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
2052,3,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
2052,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
2053,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2053,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2053,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2054,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2055,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2056,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2057,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
2057,2,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2057,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2057,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2057,5,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
2057,6,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2057,7,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2058,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2058,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2059,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2059,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2059,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2059,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2059,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2059,6,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2060,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2061,1,Asthenopia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
2061,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
2062,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2062,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2062,3,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2062,4,Oesophageal ulcer haemorrhage,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2063,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2063,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2064,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2065,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
2065,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2065,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2065,4,Completed suicide,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,Y
2065,5,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
2065,6,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2065,7,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
2065,8,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2065,9,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2065,10,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2065,11,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2065,12,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
2065,13,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
2065,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2065,15,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2065,16,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
2065,17,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2065,18,Panic reaction,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
2065,19,Phobia,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
2065,20,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
2065,21,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
2065,22,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
2065,23,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2065,24,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2066,1,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
2066,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2066,3,Pericardial calcification,Pericardial disorders NEC,Pericardial disorders,Card,N
2066,4,Pericardial haemorrhage,Pericardial disorders NEC,Pericardial disorders,Card,N
2066,5,Post procedural fistula,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2066,6,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
2067,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2067,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2067,3,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2068,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2068,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2068,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2068,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2068,5,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
2068,6,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
2068,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2068,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2069,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
2070,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2070,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2070,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2070,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2071,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2072,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2072,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2073,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2073,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2073,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2073,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2073,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2073,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2074,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2074,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2075,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2075,2,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2075,3,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
2076,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2076,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2077,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2078,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
2078,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2078,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2079,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2079,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2080,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2081,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2081,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2082,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2082,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2083,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
2083,2,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2083,3,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2084,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2085,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2086,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2087,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2088,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2088,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2089,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2090,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2090,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2091,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2091,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2092,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2093,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2094,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2095,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2096,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2097,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2097,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2098,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2098,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2099,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2099,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2099,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2100,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2101,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2101,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2102,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2102,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2102,3,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
2103,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2103,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2104,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2104,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2104,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2104,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2105,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2105,2,Gastrointestinal ulcer perforation,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
2106,1,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
2106,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2107,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2108,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2108,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2109,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2109,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2110,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2110,2,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
2110,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2110,4,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2110,5,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2110,6,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2110,7,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2110,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2110,9,Myopathy,Myopathies,Muscle disorders,Musc,N
2110,10,Overweight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
2110,11,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2110,12,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
2110,13,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2111,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2112,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2112,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2112,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2112,4,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2112,5,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2112,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2112,7,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
2112,8,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2112,9,Synovial cyst,Synovial disorders,Synovial and bursal disorders,Musc,N
2113,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2113,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2113,3,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2113,4,Haematoma infection,Vascular infections,Infections - pathogen unspecified,Infec,N
2113,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2113,6,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2113,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2113,8,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2114,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2115,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2115,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2115,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2116,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2116,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2117,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2117,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2118,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2118,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2118,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
2118,4,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
2118,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2119,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2119,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2119,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2119,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2119,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2119,6,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2119,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2119,8,Neutrophilia,Leukocytoses NEC,White blood cell disorders,Blood,N
2119,9,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2119,10,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2120,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2120,2,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
2120,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2120,4,Skin ulcer haemorrhage,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2120,5,Vascular insufficiency,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
2121,1,Breathing-related sleep disorder,Dyssomnias,Sleep disorders and disturbances,Psych,N
2121,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2121,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2121,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2121,5,Inflammation,Inflammations,General system disorders NEC,Genrl,N
2121,6,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2121,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2122,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2123,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2124,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2125,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2126,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2127,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2127,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2128,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2128,2,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2128,3,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2128,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2129,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2129,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2129,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2129,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2130,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2131,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2131,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2132,1,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
2132,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2132,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2132,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2132,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2133,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2134,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2134,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2134,3,Prothrombin time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2134,4,Renal haemorrhage,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
2134,5,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
2135,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2135,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2135,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2135,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2136,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2137,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2138,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2138,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2138,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2138,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2139,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2140,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2140,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2140,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2141,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2141,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2141,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2142,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2142,2,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2142,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2143,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2144,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2144,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2144,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2145,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2146,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2147,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2148,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2148,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2149,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2150,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2151,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2151,2,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2151,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2151,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2151,5,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2151,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2151,7,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2152,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2153,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
2153,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2153,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2153,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2154,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2154,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2155,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2156,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2156,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2156,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2156,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2156,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2156,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2157,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2158,1,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
2159,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2159,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2159,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2160,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2160,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2160,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2160,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2160,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2161,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2162,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2163,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2163,2,Ocular icterus,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2163,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2163,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2163,5,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2164,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2165,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2165,2,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
2165,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2166,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2166,2,Headache,Headaches NEC,Headaches,Nerv,N
2166,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2167,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2168,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2168,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2169,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2169,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2169,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2169,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2170,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2170,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2170,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2170,4,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2170,5,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2171,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2172,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2172,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2172,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2173,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2173,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2173,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2173,4,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2173,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2173,6,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2173,7,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2173,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2173,9,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2173,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2173,11,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2174,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2174,2,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
2175,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2175,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2175,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
2176,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2176,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2176,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2177,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2177,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2178,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2179,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2180,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2181,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2182,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2183,1,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2184,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2185,1,Drug level changed,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2185,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2186,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2187,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2188,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2188,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2189,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2190,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2191,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2192,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2193,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2194,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2195,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2196,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2197,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2197,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2198,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2199,1,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2200,1,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2201,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2202,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2203,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2204,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2204,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2205,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2206,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2206,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2206,3,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2206,4,Pharyngeal haemorrhage,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2206,5,Tongue haematoma,Tongue disorders,Tongue conditions,Gastr,N
2207,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2207,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2207,3,Nail growth abnormal,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
2208,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2208,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2208,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2209,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2210,1,Eye inflammation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
2210,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2211,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2212,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2212,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2213,1,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2214,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2215,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2215,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2215,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2215,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2215,5,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2216,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2217,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2217,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2218,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2218,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2218,3,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
2219,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2220,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2220,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2220,3,Headache,Headaches NEC,Headaches,Nerv,N
2221,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
2221,2,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
2221,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2222,1,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
2222,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2222,3,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2222,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2222,5,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2222,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
2222,7,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2222,8,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2223,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2223,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2223,3,Haematoma infection,Vascular infections,Infections - pathogen unspecified,Infec,N
2223,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2224,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2224,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2225,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2225,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2226,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2227,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2227,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2228,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2228,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2229,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2230,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2230,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2231,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2231,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2232,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2232,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2232,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2232,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2233,1,Atrial flutter,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2233,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2233,3,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
2233,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2234,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2235,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2235,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2236,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2236,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2236,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2237,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2237,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2237,3,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2238,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2238,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2238,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2238,4,Morbid thoughts,Thinking disturbances,Disturbances in thinking and perception,Psych,N
2238,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2239,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2240,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2240,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2241,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2241,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2241,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2242,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,Y
2242,2,Soft tissue haemorrhage,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2243,1,Basal ganglia haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2243,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2243,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2243,4,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,Y
2243,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2243,6,Systolic hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2244,1,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2244,2,Haemorrhagic ovarian cyst,Ovarian and fallopian tube cysts and neoplasms,Ovarian and fallopian tube disorders,Repro,N
2245,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2245,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2245,3,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2246,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2247,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2247,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2248,1,Coarctation of the aorta,Great vessel disorders congenital,Cardiac and vascular disorders congenital,Cong,N
2248,2,Congenital nose malformation,Nasal disorders congenital,Respiratory disorders congenital,Cong,N
2248,3,Congenital pharyngeal anomaly,Pharyngeal disorders congenital,Respiratory disorders congenital,Cong,N
2248,4,Dandy-Walker syndrome,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
2248,5,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
2248,6,Gastroschisis,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
2248,7,Ventricular septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
2249,1,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2250,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2250,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2250,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2251,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2251,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2251,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2252,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2252,2,Femoral nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
2252,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2252,4,Radiculopathy,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
2252,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2253,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2254,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2255,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2256,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2256,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2257,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2257,2,Vaginal mucosal blistering,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2258,1,Osteoporotic fracture,Fractures NEC,Fractures,Musc,N
2259,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2259,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2259,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2260,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2260,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2260,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2261,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2262,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2262,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2263,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2264,1,Bone erosion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
2264,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2264,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2264,4,Ligament injury,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
2264,5,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
2265,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2265,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2266,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2267,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2267,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2267,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2267,4,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2267,5,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2267,6,Therapeutic embolisation,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
2268,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2268,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2268,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2269,1,Osteopenia,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
2269,2,Spinal compression fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
2270,1,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
2270,2,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
2270,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2271,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2272,1,Spontaneous haematoma,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2273,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2274,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2274,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2274,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2274,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2274,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2274,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2274,7,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2274,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
2274,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2274,10,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
2274,11,Rales,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2274,12,Rales,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2274,13,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
2274,14,Stridor,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
2274,15,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2274,16,Venous pressure jugular increased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2275,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
2275,2,Bladder perforation,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
2275,3,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2275,4,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2275,5,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2275,6,Disseminated Bacillus Calmette-Guerin infection,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
2275,7,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2275,8,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2275,9,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2275,10,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2275,11,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2275,12,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2275,13,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2276,1,Breast mass,Breast disorders NEC,Breast disorders,Repro,N
2276,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2277,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2277,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2277,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
2277,4,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2277,5,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2277,6,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2277,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2278,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2278,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2278,3,Electrocardiogram abnormal,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2278,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2278,5,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2278,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2278,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
2278,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2278,9,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
2278,10,Rales,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2278,11,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
2278,12,Stridor,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
2278,13,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2279,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2280,1,Priapism,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
2281,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2281,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2282,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2282,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2282,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2283,1,Auricular haematoma,Ear injuries NEC,Injuries NEC,Inj&P,N
2283,2,Protein S decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2284,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2284,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2284,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2284,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2284,5,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2284,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2284,7,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2285,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2285,2,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2285,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2285,4,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2285,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2286,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2287,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2287,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2288,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2289,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
2289,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2290,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2290,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2290,3,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2291,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2291,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2291,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2292,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2292,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2292,3,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2292,4,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2292,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2293,1,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2294,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2294,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2294,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2295,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2295,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2296,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2296,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2296,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2296,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2297,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2297,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2297,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2297,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2298,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2298,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2299,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2299,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2299,3,Walking aid user,Disability issues,Lifestyle issues,SocCi,N
2300,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2300,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2300,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2300,4,Uterine dilation and evacuation,Uterine therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
2300,5,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2301,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2302,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2302,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2302,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2303,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2304,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2304,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2305,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2305,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2306,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
2307,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2307,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2307,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2308,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2308,2,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
2308,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2309,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2310,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2311,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2311,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2311,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2311,4,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
2311,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2311,6,Headache,Headaches NEC,Headaches,Nerv,N
2311,7,Hyperacusis,Hyperacusia,Hearing disorders,Ear,N
2311,8,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
2311,9,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
2311,10,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
2312,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2312,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2313,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
2313,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2314,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2314,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2314,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
2314,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2314,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2315,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2315,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2315,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2315,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2316,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2317,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2317,2,Hypovolaemia,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,Y
2317,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2317,4,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2317,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2318,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2318,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2318,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
2319,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2319,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2320,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2321,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2322,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2322,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2323,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2323,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2324,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2324,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2324,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2324,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2324,5,Hypothermia,Body temperature altered,Body temperature conditions,Genrl,N
2324,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2324,7,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2324,8,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2324,9,Pericardial haemorrhage,Pericardial disorders NEC,Pericardial disorders,Card,Y
2324,10,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2325,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2325,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2325,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2325,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2325,5,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2325,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2326,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2326,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2327,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2327,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2328,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2328,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2328,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2329,1,Exposure to noise,Non-occupational environmental exposures,"Exposures, chemical injuries and poisoning",Inj&P,N
2329,2,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2329,3,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2330,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2330,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2331,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2332,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
2332,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2333,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2333,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2333,3,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2334,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2335,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2335,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2336,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2336,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2336,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2336,4,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2336,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2337,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2337,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2338,1,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2339,1,Exophthalmos,"Structural change, deposit and degeneration of eye NEC","Ocular structural change, deposit and degeneration NEC",Eye,N
2339,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2339,3,Ophthalmoplegia,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
2339,4,Pupil fixed,Pupil disorders,Ocular neuromuscular disorders,Eye,N
2339,5,Pupillary reflex impaired,Pupil disorders,Ocular neuromuscular disorders,Eye,N
2339,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2340,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2341,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2341,2,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2342,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2342,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
2342,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2343,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2343,2,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2344,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2345,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2345,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2346,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2346,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2347,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2347,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2348,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2348,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2348,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2348,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2349,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2349,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2349,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2350,1,Deafness,Hearing losses,Hearing disorders,Ear,N
2350,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2350,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2350,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2350,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2350,6,Temperature intolerance,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2351,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2351,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2351,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2352,1,Erythroplasia,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2352,2,Leukoplakia,Skin preneoplastic conditions NEC,Cornification and dystrophic skin disorders,Skin,N
2352,3,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
2353,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2353,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2354,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2354,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2355,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2355,2,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
2355,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2355,4,Hepatitis cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2355,5,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
2355,6,Hyporeflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
2355,7,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
2355,8,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2355,9,Mesenteric artery thrombosis,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2355,10,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2356,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2357,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2358,1,Hepatitis cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2359,1,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
2359,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
2359,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
2360,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2360,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2360,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2360,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2360,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2361,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2361,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2361,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2362,1,Hepatitis cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2362,2,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2362,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2363,1,Hepatitis cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2364,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2365,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2366,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2367,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2367,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2368,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2369,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2370,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2370,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2370,3,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2370,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2371,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2372,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2372,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2372,3,Partial seizures,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
2372,4,Trismus,Muscle tone abnormalities,Muscle disorders,Musc,N
2373,1,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
2374,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2375,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2376,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2376,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2377,1,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
2377,2,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2377,3,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2378,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2379,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2379,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2379,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2379,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2380,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2380,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2381,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2381,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2382,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2382,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2383,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2383,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2383,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2384,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2384,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2384,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2385,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2385,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2386,1,Abnormal faeces,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2386,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
2386,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2386,4,Dysentery,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
2386,5,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
2386,6,Urine odour abnormal,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2387,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2387,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2387,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2387,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2387,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2387,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2388,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2389,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2390,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2390,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2391,1,Auricular haematoma,Ear injuries NEC,Injuries NEC,Inj&P,N
2391,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2392,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2392,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2392,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2393,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2393,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2393,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2394,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
2394,2,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
2394,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2394,4,Dilatation ventricular,Myocardial disorders NEC,Myocardial disorders,Card,N
2394,5,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2394,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2395,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2395,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2396,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2397,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2397,2,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2397,3,Blindness transient,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2397,4,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
2397,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2397,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2397,7,Headache,Headaches NEC,Headaches,Nerv,N
2397,8,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2397,9,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2397,10,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
2397,11,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2397,12,Visual field defect,Visual field disorders,Vision disorders,Eye,N
2398,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2398,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2399,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2400,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2400,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2400,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
2401,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2401,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2402,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2402,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2403,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2404,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2404,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2405,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2405,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2406,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2406,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2407,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2407,2,Headache,Headaches NEC,Headaches,Nerv,N
2407,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2407,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2408,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2409,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2409,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2410,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2410,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2410,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2410,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2410,5,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2411,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2411,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2411,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2412,1,Infusion site haemorrhage,Infusion site reactions,Administration site reactions,Genrl,N
2412,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2412,3,Venous haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2413,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2414,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2414,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2414,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2414,4,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2414,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2415,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2415,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2416,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2416,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2417,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2417,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2417,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2418,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2418,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2418,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2418,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2419,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2419,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2420,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2420,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
2420,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2421,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2421,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2422,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2422,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2423,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2424,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2425,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2425,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2425,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2425,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2426,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2426,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2426,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2427,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2427,2,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2427,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2427,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2428,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2428,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2429,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2430,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2430,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2430,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2430,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2430,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2431,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2431,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2431,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2432,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
2432,2,Salivary hyposecretion,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
2433,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
2433,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
2433,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2433,4,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2434,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2434,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2434,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2435,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2435,2,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2435,3,Small intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2436,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2436,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2437,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2438,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2438,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2438,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2438,4,Pericardial haemorrhage,Pericardial disorders NEC,Pericardial disorders,Card,Y
2438,5,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
2439,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2439,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2439,3,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
2439,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2439,5,Pericardial haemorrhage,Pericardial disorders NEC,Pericardial disorders,Card,Y
2440,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2440,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2440,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2441,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2441,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2441,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2441,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2441,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2441,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2442,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2443,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2443,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2443,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2443,4,Headache,Headaches NEC,Headaches,Nerv,N
2443,5,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
2443,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2443,7,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2443,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2443,9,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2443,10,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2443,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2443,12,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2443,13,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2444,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2444,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2444,3,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2444,4,Corneal oedema,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
2444,5,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2444,6,Flat anterior chamber of eye,"Anterior chamber structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
2444,7,Ocular hyperaemia,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
2445,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2445,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2445,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2445,4,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2445,5,Visual field defect,Visual field disorders,Vision disorders,Eye,N
2446,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2446,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2447,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2447,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2448,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2449,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2450,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2450,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2451,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2451,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2452,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2452,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2453,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2453,2,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
2453,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2454,1,Atrial tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2455,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2455,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2455,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2455,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2455,5,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2456,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2457,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2457,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2458,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2458,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2458,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2459,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2460,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2461,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2461,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
2461,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2461,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2461,5,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2461,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2462,1,Headache,Headaches NEC,Headaches,Nerv,N
2462,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2463,1,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
2464,1,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2464,2,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2465,1,Anal incontinence,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
2465,2,Areflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
2465,3,Catheter placement,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
2465,4,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2465,5,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
2465,6,Haematoma evacuation,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
2465,7,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2465,8,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2465,9,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2465,10,Spinal laminectomy,Spine and spinal cord therapeutic procedures,"Nervous system, skull and spine therapeutic procedures",Surg,N
2465,11,Spinal pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
2465,12,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2465,13,Wheelchair user,Disability issues,Lifestyle issues,SocCi,N
2466,1,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2466,2,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2467,1,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2467,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2467,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2467,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
2467,5,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
2467,6,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2467,7,Wheelchair user,Disability issues,Lifestyle issues,SocCi,N
2468,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2468,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2468,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2468,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2468,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2469,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2470,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2470,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2470,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2470,4,Haematoma evacuation,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
2470,5,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2471,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2471,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2471,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2472,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2472,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2473,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2474,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
2474,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
2475,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2475,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2476,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2476,2,Headache,Headaches NEC,Headaches,Nerv,N
2476,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2477,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2477,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2478,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2479,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2479,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2479,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
2479,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2480,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2481,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2482,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2483,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2483,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2483,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2483,4,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2484,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2485,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2485,2,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2485,3,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2485,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2486,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2486,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2486,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2487,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2488,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2488,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2488,3,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2489,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2489,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2490,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2491,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2491,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2492,1,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
2493,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2494,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2494,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2494,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
2494,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2494,5,Headache,Headaches NEC,Headaches,Nerv,N
2494,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2494,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2495,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2495,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2496,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2496,2,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
2497,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2497,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2498,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2498,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2499,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2499,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2500,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2500,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2501,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2502,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2502,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2502,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2503,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2504,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2504,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2505,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2505,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2506,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2507,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2508,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2508,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2509,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2509,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2510,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2510,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2510,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2511,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2512,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2512,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2512,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2512,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2512,5,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2512,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,Y
2512,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2513,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2513,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2513,3,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
2513,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2514,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2514,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2515,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2515,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2515,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
2515,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2515,5,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
2515,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2515,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2515,8,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2515,9,Subcutaneous haematoma,Skin injuries NEC,Injuries NEC,Inj&P,N
2515,10,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2516,1,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2517,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2518,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2518,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2519,1,Acne,Acnes,Skin appendage conditions,Skin,N
2519,2,Headache,Headaches NEC,Headaches,Nerv,N
2519,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2520,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2521,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2521,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2521,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2521,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2521,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2521,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2521,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2521,8,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
2522,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2522,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2523,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2524,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2525,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2526,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2527,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2527,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2527,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
2527,4,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2527,5,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2528,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2528,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2528,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2528,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2529,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2529,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2529,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2530,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2530,2,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
2531,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2531,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2532,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2532,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2532,3,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2532,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2532,5,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2532,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2533,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2534,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2534,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2534,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2535,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2535,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2536,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2536,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2536,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2536,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2537,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2537,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2538,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2538,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2538,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2539,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
2540,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2540,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2540,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2541,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2542,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2543,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2544,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2544,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2544,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2545,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2546,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2546,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2546,3,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2547,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2547,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2548,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2548,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2548,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2548,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
2548,5,Diastolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
2548,6,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
2548,7,Headache,Headaches NEC,Headaches,Nerv,N
2548,8,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2548,9,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2548,10,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2548,11,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2548,12,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2549,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2549,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2549,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2549,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2549,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2550,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2551,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2551,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2552,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2553,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2553,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2554,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2554,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2555,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2555,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2555,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2555,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2555,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2556,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2556,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2557,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2557,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2557,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2557,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2557,5,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2557,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2558,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2558,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2559,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2559,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2560,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2560,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2560,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2560,4,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2560,5,Headache,Headaches NEC,Headaches,Nerv,N
2560,6,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
2560,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2560,8,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2560,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2560,10,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2560,11,Spontaneous hyphaema,Anterior chamber bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2560,12,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2561,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
2561,2,Aortic dissection,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
2561,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2561,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2561,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2561,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2561,7,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2561,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2561,9,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
2561,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2561,11,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2561,12,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2562,1,Conjunctival degeneration,"Conjunctival structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
2562,2,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2562,3,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
2562,4,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
2562,5,Lagophthalmos,"Lid, lash and lacrimal structural disorders","Anterior eye structural change, deposit and degeneration",Eye,N
2562,6,Tear discolouration,Lacrimation disorders,Eye disorders NEC,Eye,N
2563,1,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2563,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2564,1,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2564,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2565,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2566,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2566,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2567,1,Focal dyscognitive seizures,Partial complex seizures,Seizures (incl subtypes),Nerv,N
2567,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
2567,3,Porencephaly,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
2567,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
2568,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2569,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2570,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2571,1,Decubitus ulcer,Skin injuries and mechanical dermatoses,Epidermal and dermal conditions,Skin,N
2571,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2572,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2572,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2572,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2573,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2574,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2575,1,Coagulation time abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2575,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2576,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2576,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2577,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2577,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2577,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2578,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2578,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2579,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2579,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2580,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2580,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2581,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2581,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2581,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2581,4,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
2581,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2582,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2582,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2582,3,Blood bilirubin abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2582,4,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2582,5,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2582,6,Gastrointestinal tube insertion,Gastrointestinal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
2582,7,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2582,8,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2582,9,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2583,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2583,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2583,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2583,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2584,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2584,2,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2584,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2584,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2584,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2585,1,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,N
2585,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2585,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2585,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2585,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
2586,1,Gastric antral vascular ectasia,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
2587,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2587,2,Micturition urgency,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
2587,3,Renal cyst,Renal neoplasms,Renal disorders (excl nephropathies),Renal,N
2588,1,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
2588,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2589,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2590,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2590,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2590,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2591,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2591,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2591,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2591,4,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
2592,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2593,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2594,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2595,1,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2596,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2597,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2598,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2599,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2600,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2601,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2601,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2602,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2602,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2602,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2602,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2602,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2603,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2604,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2604,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2605,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2606,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2606,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2606,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2606,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2606,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2607,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2608,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2608,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2609,1,Pre-existing condition improved,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2610,1,Intestinal infarction,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2610,2,Mesenteric vein thrombosis,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2610,3,Protein S deficiency,Coagulation disorders congenital,Blood and lymphatic system disorders congenital,Cong,N
2611,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2611,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2611,3,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
2612,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2612,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2613,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2613,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2613,3,Uterine leiomyoma,Uterine neoplasms benign,Reproductive neoplasms female benign,Neopl,N
2613,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2614,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2614,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2615,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2615,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2616,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2616,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2616,3,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2616,4,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2616,5,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2616,6,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2616,7,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2616,8,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2616,9,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2616,10,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
2616,11,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2616,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2616,13,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2616,14,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2617,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
2617,2,Hangover,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2618,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2618,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2619,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2619,2,Headache,Headaches NEC,Headaches,Nerv,N
2620,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2620,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2620,3,Laryngeal haematoma,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2621,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2621,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2622,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2623,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2623,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2624,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
2624,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2624,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2624,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2624,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2624,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2625,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2625,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2625,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2626,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2626,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2626,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2626,4,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2627,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2627,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2627,3,Laryngeal haematoma,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2627,4,Upper airway obstruction,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2628,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2628,2,Laryngeal haematoma,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2629,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2629,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2629,3,Laryngeal haematoma,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2629,4,Upper airway obstruction,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2630,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2630,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2631,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2632,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2633,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2633,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2634,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2635,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2635,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2635,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
2636,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2637,1,Body temperature decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2637,2,Headache,Headaches NEC,Headaches,Nerv,N
2637,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2637,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2637,5,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2637,6,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2638,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2639,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2639,2,Extrasystoles,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2639,3,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2639,4,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2639,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2640,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2640,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2641,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2642,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2642,2,Wound haemorrhage,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2643,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2644,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2644,2,Cardiac failure chronic,Heart failures NEC,Heart failures,Card,N
2644,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2644,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2644,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2645,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2645,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2646,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2646,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2647,1,Pseudofolliculitis,Pilar disorders NEC,Skin appendage conditions,Skin,N
2648,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2648,2,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
2649,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2649,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2649,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2650,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2651,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2651,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2652,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2652,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2653,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2653,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2654,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2654,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2655,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2655,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2656,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2656,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2656,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2657,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2657,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2658,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
2659,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2660,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2660,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2661,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2661,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2662,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2663,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2664,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2665,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2666,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2666,2,Drug level changed,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2667,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2667,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2667,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2667,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2667,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2667,6,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2668,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2669,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2670,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2670,2,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
2670,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2670,4,Thyroid function test abnormal,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
2671,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2672,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
2673,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2674,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2674,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2674,3,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2674,4,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
2674,5,Sinus headache,Headaches NEC,Headaches,Nerv,N
2674,6,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
2675,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2675,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2675,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2675,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2676,1,Abdominal wall haemorrhage,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2676,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2676,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2677,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
2678,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2678,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2678,3,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2678,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2678,5,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2678,6,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
2678,7,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
2678,8,Sarcoma,Soft tissue sarcomas histology unspecified,Soft tissue neoplasms malignant and unspecified,Neopl,N
2679,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2679,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2680,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2680,2,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
2681,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2681,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2681,3,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2681,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2682,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2682,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2683,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2683,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2683,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2683,4,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2683,5,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2684,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
2685,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2685,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2685,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2685,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2686,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2686,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2686,3,Haemorrhagic disorder,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2686,4,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,Y
2686,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2687,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2687,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2688,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2688,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2688,3,Large intestinal ulcer haemorrhage,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
2689,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2689,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2690,1,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
2691,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2691,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2692,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2692,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2693,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2694,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2695,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2695,2,Haemorrhagic disorder,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,Y
2696,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2696,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2697,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2697,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2698,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2699,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2699,2,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
2699,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2699,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2699,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2699,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
2699,7,Polymyalgia rheumatica,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
2699,8,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2700,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2700,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2701,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2701,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2702,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2702,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2702,3,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2702,4,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
2702,5,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2702,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2702,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2702,8,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2702,9,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2702,10,Pericardial haemorrhage,Pericardial disorders NEC,Pericardial disorders,Card,N
2702,11,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
2702,12,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2702,13,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2703,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2703,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2703,3,Salivary gland mass,Salivary gland disorders NEC,Salivary gland conditions,Gastr,N
2704,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2704,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2705,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2705,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2706,1,Enzyme induction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2706,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2707,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2707,2,Cerebral venous thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
2707,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2707,4,Neurological complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
2707,5,Product administered to patient of inappropriate age,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2707,6,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2708,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2709,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2710,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2711,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2711,2,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
2712,1,Acne,Acnes,Skin appendage conditions,Skin,N
2712,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2712,3,Breath odour,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
2712,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2712,5,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2712,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
2712,7,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2712,8,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2712,9,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
2712,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2712,11,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2712,12,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2712,13,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
2712,14,Functional gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2712,15,Gastric dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2712,16,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2712,17,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2712,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2712,19,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2712,20,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2713,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2713,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2713,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2713,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2713,5,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2714,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
2714,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2714,3,Eschar,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2714,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2714,5,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2714,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2714,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2714,8,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2714,9,Skin odour abnormal,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2714,10,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2715,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2716,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2716,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2717,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2717,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2718,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2719,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2719,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2720,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2720,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
2720,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2721,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2721,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2721,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2722,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2722,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2723,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2723,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
2723,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2724,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2724,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2725,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2725,2,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2725,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2725,4,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
2726,1,Abdominal compartment syndrome,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,Y
2726,2,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2726,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2727,1,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2727,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2727,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2727,4,Incision site haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
2727,5,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
2727,6,Tongue paralysis,Hypoglossal nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
2728,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2728,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2729,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2729,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2729,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2730,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2730,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2730,3,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
2731,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2731,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
2731,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2732,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2732,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2733,1,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
2734,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2734,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
2735,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2735,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2735,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
2735,4,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2736,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2736,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2736,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2737,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2737,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2738,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2738,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2739,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2739,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2739,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2740,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2740,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2741,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2741,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2741,3,Headache,Headaches NEC,Headaches,Nerv,N
2742,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2743,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2743,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2743,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2743,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2743,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2744,1,Mesenteric vein thrombosis,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,N
2744,2,Protein S deficiency,Coagulation disorders congenital,Blood and lymphatic system disorders congenital,Cong,N
2744,3,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
2745,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2745,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2745,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2746,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2746,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2747,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2747,2,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
2748,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2748,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2748,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2749,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2749,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2750,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2751,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2752,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2752,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2753,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2753,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2753,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
2754,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2755,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2755,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2756,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2757,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2757,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2758,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2759,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2760,1,Arthritis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2760,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2760,3,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2761,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
2761,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2761,3,Headache,Headaches NEC,Headaches,Nerv,N
2761,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2762,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2762,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2762,3,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
2763,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2763,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2764,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2764,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2764,3,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2764,4,Hypercoagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2764,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2764,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2764,7,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2765,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2765,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2765,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2765,4,Peptic ulcer,Peptic ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2766,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2767,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2767,2,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
2767,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2767,4,Rebound effect,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2767,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2768,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2769,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2769,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2769,3,Disability,Disability issues,Lifestyle issues,SocCi,N
2769,4,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2769,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2769,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2769,7,Walking disability,Disability issues,Lifestyle issues,SocCi,N
2770,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2771,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2772,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2772,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2773,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2773,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2774,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2774,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2775,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2775,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2776,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2776,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2776,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2777,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2777,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2778,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2778,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2779,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2779,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2780,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2780,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2780,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2781,1,Cerebral haemorrhage foetal,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2781,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2781,3,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2782,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2782,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2783,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2784,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
2784,2,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2784,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2785,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2785,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2785,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2786,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2786,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2786,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2787,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2787,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2787,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2788,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2788,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2788,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2789,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2790,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2790,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2791,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2791,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2792,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2792,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2792,3,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2792,4,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2792,5,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2792,6,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2792,7,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2792,8,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2792,9,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2792,10,Colostomy,Large intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
2792,11,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2792,12,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2792,13,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2792,14,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
2792,15,Diverticulum intestinal,Diverticula,Diverticular disorders,Gastr,N
2792,16,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2792,17,Faecal vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2792,18,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2792,19,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2792,20,Intestinal dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2792,21,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
2792,22,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2792,23,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2792,24,Neutrophilia,Leukocytoses NEC,White blood cell disorders,Blood,N
2792,25,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2792,26,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2792,27,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2793,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
2794,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2794,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2795,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2795,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2795,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2796,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2797,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2798,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2799,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2799,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2799,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2800,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2800,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2801,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2802,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2803,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2803,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2804,1,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2805,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2806,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2806,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2807,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2807,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2807,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2808,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2808,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2808,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2808,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2809,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2809,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
2809,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2809,4,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
2809,5,Nosocomial infection,Infectious transmissions,Ancillary infectious topics,Infec,N
2809,6,Paraplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2809,7,Spinal subdural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2809,8,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
2810,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2810,2,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,Y
2810,3,Aortic rupture,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2810,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2810,5,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2810,6,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2810,7,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2810,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2810,9,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2810,10,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2810,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2810,12,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
2811,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2811,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2811,3,Congenital anaemia,Anaemias congenital (excl haemoglobinopathies),Blood and lymphatic system disorders congenital,Cong,N
2811,4,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2811,5,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
2811,6,Foetal-maternal haemorrhage,Foetal complications NEC,Foetal complications,Preg,N
2811,7,Hyperlactacidaemia,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
2811,8,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2811,9,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
2811,10,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
2811,11,Thrombocytopenia neonatal,Thrombocytopenias,Platelet disorders,Blood,N
2812,1,Thrombotic cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2813,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2813,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2814,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2815,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2815,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2815,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2816,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2817,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2817,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2817,3,Ventricular arrhythmia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2817,4,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2818,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2818,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2818,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2819,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2819,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2819,3,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
2820,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2820,2,Live birth,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
2821,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2821,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2821,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2821,4,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
2821,5,Foetal-maternal haemorrhage,Foetal complications NEC,Foetal complications,Preg,N
2822,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2822,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2822,3,Gastrointestinal motility disorder,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2822,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2822,5,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2822,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2822,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2823,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2823,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2823,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2824,1,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
2825,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2825,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2825,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2826,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2826,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2827,1,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2827,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2828,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2828,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2828,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2828,4,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2828,5,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2829,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2830,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2830,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2830,3,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
2830,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2830,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
2830,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2830,7,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2830,8,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2831,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2831,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2831,3,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
2831,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
2832,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2833,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2833,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2834,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2834,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2835,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2835,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2835,3,Intestinal haematoma,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2835,4,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
2835,5,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
2835,6,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
2836,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2836,2,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
2836,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
2837,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2838,1,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
2839,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2840,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
2840,2,Pancreatolithiasis,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
2841,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2841,2,Foetal-maternal haemorrhage,Foetal complications NEC,Foetal complications,Preg,N
2842,1,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
2842,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2843,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2843,2,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2843,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2843,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2843,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2843,6,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
2843,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2844,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2844,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2845,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2846,1,Bone density decreased,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
2846,2,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
2846,3,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2846,4,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2846,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
2846,6,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2846,7,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
2847,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2847,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2848,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2849,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2849,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2849,3,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2849,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2849,5,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2849,6,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2849,7,Dysbiosis,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2849,8,Inflammation,Inflammations,General system disorders NEC,Genrl,N
2849,9,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
2849,10,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2849,11,Popliteal pulse,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2849,12,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2849,13,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2849,14,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2849,15,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2849,16,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
2849,17,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2849,18,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
2849,19,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
2850,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2850,2,Bone density decreased,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
2850,3,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
2850,4,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2850,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2850,6,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2850,7,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2850,8,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2850,9,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2850,10,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
2850,11,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2850,12,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2851,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2851,2,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2851,3,Areflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
2851,4,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2851,5,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2851,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2851,7,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2851,8,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2852,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2852,2,Coagulation test abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2852,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2852,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2852,5,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2852,6,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2852,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2853,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2854,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2854,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2854,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2855,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
2855,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
2856,1,Change of bowel habit,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2856,2,Defaecation urgency,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
2856,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2856,4,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2856,5,Functional gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2856,6,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
2857,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2857,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2858,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2858,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2858,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2859,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2859,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2860,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2860,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2861,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2862,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2863,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2863,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2864,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2864,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2864,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2865,1,Angina unstable,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2865,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2866,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2866,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2867,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2868,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2868,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
2868,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2868,4,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2868,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2868,6,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2868,7,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2868,8,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2868,9,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
2868,10,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
2868,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2869,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2869,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2870,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2870,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2871,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2872,1,Hair growth abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
2873,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2873,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
2873,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2874,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2875,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2875,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2875,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2875,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2875,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2876,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2877,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2877,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2878,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2879,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2880,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
2880,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2881,1,Infusion site extravasation,Infusion site reactions,Administration site reactions,Genrl,N
2881,2,Infusion site necrosis,Infusion site reactions,Administration site reactions,Genrl,N
2881,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2882,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2882,2,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2882,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2883,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2883,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2884,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2884,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2885,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2885,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2885,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2886,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2887,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
2888,1,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
2888,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2888,3,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2889,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2889,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2890,1,Headache,Headaches NEC,Headaches,Nerv,N
2890,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2890,3,Vitreous floaters,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
2891,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2891,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2891,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2891,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2892,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2892,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2893,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2893,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2893,3,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2893,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2894,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2894,2,Headache,Headaches NEC,Headaches,Nerv,N
2894,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2894,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
2894,5,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2894,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2895,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2895,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
2895,3,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2895,4,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
2895,5,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2895,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
2896,1,Migraine,Migraine headaches,Headaches,Nerv,N
2896,2,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2896,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2897,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
2897,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2897,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
2897,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2897,5,Headache,Headaches NEC,Headaches,Nerv,N
2897,6,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2897,7,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2897,8,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
2897,9,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
2898,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2898,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2898,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2898,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
2898,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2899,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2899,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2900,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2900,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2900,3,Headache,Headaches NEC,Headaches,Nerv,N
2901,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2902,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2902,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2903,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2903,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
2903,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2903,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
2903,5,Ureteric obstruction,Ureteric disorders NEC,Ureteric disorders,Renal,N
2904,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2905,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2906,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2907,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2907,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,Y
2907,3,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2908,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2909,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2909,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
2910,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
2910,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2911,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2912,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2913,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
2913,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
2913,3,Splenic haematoma,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
2913,4,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
2913,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2914,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2914,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2915,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2916,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2916,2,Incorrect product dosage form administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2916,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2917,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
2917,2,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
2918,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2919,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2919,2,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
2919,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2920,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2920,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
2921,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2921,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2921,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2921,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
2921,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2922,1,Intracranial haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2923,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
2923,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
2923,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2923,4,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2923,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2923,6,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2923,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2924,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2924,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2924,3,Hiatus hernia,Diaphragmatic hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
2924,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2924,5,Varices oesophageal,Oesophageal varices,Gastrointestinal vascular conditions,Gastr,N
2925,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2925,2,Headache,Headaches NEC,Headaches,Nerv,N
2925,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2925,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2926,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2927,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
2927,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2927,3,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2927,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2928,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2928,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2928,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2929,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2929,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
2930,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2930,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2931,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2932,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2932,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2932,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2933,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
2933,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2934,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
2934,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2935,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2935,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2936,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2936,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2937,1,Electric shock sensation,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2937,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2937,3,Headache,Headaches NEC,Headaches,Nerv,N
2937,4,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2937,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2937,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2938,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2939,1,Erosive duodenitis,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2939,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2939,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2939,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2940,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2940,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2941,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2941,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2942,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2942,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2942,3,Hypersomnia,Narcolepsy and hypersomnia,Sleep disturbances (incl subtypes),Nerv,N
2942,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
2943,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2944,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2945,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2945,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2946,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
2946,2,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
2947,1,Dizziness postural,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2947,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
2948,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2948,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2948,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2948,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2949,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2949,2,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2950,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2950,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2950,3,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
2951,1,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
2952,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
2953,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2953,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2953,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2954,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2954,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2955,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
2955,2,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
2956,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2956,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2956,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2957,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2958,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2958,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2959,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2959,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2959,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2960,1,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2961,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2961,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2961,3,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
2961,4,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
2961,5,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2961,6,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
2962,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2962,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2963,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2963,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2964,1,Aortic aneurysm rupture,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,Y
2965,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2966,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2966,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2966,3,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
2966,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2966,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2966,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2966,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2967,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2967,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2967,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2967,4,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2967,5,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
2968,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2968,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2968,3,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
2968,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2969,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2970,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
2971,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2971,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2971,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2972,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2972,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2972,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2973,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2974,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,Y
2974,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2974,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2974,4,Vascular injury,Cardiovascular injuries,Injuries NEC,Inj&P,N
2974,5,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2975,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
2975,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2975,3,Mucosal haemorrhage,Mucosal findings abnormal,General system disorders NEC,Genrl,N
2975,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2976,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2976,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2976,3,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2976,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2977,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2977,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2977,3,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2977,4,Pneumonia aspiration,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2977,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
2977,6,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
2978,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2979,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2979,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2979,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2979,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
2980,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2981,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2981,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2981,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
2982,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2982,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2982,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2982,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2983,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2984,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2984,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2985,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2986,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
2987,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2987,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2988,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2989,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2989,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2990,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2991,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2992,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
2992,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
2992,3,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
2993,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2993,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2994,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2994,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2995,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2995,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
2995,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2996,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2996,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2996,3,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2996,4,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
2996,5,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
2996,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2996,7,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2996,8,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2997,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2998,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2999,1,Urge incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3000,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3000,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
3000,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3000,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3000,5,Secretion discharge,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3000,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
3001,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3001,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3002,1,Arterial thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3002,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3002,3,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3002,4,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3002,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3002,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3002,7,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3002,8,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3002,9,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3003,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3003,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3003,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3004,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3004,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3004,3,Headache,Headaches NEC,Headaches,Nerv,N
3004,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3004,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3004,6,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
3005,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3005,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3005,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
3005,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3005,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3005,6,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3005,7,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3005,8,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3005,9,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3005,10,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3005,11,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3005,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3005,13,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3005,14,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3006,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3006,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3007,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
3008,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3008,2,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3008,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3008,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3008,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3008,6,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3008,7,Muscle oedema,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3008,8,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3008,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3008,10,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3008,11,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3008,12,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3009,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3009,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3009,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3009,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3009,5,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
3010,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3010,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3010,3,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3011,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3012,1,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
3013,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3013,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3014,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3014,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3014,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3014,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3014,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3014,6,Muscle oedema,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3014,7,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3014,8,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3014,9,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3014,10,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3014,11,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3014,12,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3015,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3015,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3016,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3017,1,Skin odour abnormal,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3018,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3018,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3018,3,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3019,1,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
3019,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3019,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3019,4,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
3019,5,Headache,Headaches NEC,Headaches,Nerv,N
3019,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3019,7,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3019,8,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3019,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3020,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3020,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3021,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3021,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3022,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3022,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3022,3,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3023,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3023,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3024,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3024,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3024,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3025,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3025,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3025,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3026,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3026,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3027,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3027,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3027,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3027,4,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3028,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
3028,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
3029,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3029,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3030,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3030,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3030,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3031,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
3031,2,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3031,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3031,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3031,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3031,6,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
3032,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3032,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3032,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3032,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3033,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3033,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3033,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3033,4,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3033,5,Normochromic normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3033,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3033,7,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3033,8,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3034,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3034,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
3035,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3035,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3036,1,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
3037,1,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3037,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3038,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
3039,1,Herbal interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3039,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3040,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3040,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3040,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3040,4,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3041,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3041,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3041,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3042,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3042,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3042,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
3043,1,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
3044,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3044,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3044,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
3045,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3045,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3045,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3045,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
3045,5,Vitreous floaters,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
3046,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3047,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3047,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3048,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3049,1,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
3050,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3050,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3051,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
3051,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3051,3,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3051,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
3052,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3053,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3054,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
3054,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3054,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3055,1,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3055,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3055,3,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3056,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3056,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3056,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
3057,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3058,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3059,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3060,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3061,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3061,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3062,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3063,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3063,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3063,3,Foreign body,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3063,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3063,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3064,1,Haemobilia,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3065,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3065,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3066,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3066,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3066,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3066,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3067,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3067,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
3068,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3069,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3070,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3070,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3071,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3072,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3073,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3073,2,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3073,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3074,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3074,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3075,1,Apraxia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
3075,2,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3075,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3075,4,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
3075,5,Headache,Headaches NEC,Headaches,Nerv,N
3075,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3076,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3076,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3076,3,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
3076,4,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3076,5,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3076,6,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3076,7,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
3076,8,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3076,9,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3076,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3076,11,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3076,12,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3076,13,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
3076,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3076,15,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3077,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3077,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3078,1,Vasculitis necrotising,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
3079,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3079,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3080,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3080,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3080,3,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
3081,1,Headache,Headaches NEC,Headaches,Nerv,N
3081,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3082,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3082,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3082,3,Ischaemia,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3082,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3082,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3082,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3082,7,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3082,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3082,9,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3082,10,Weight bearing difficulty,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3083,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3083,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3084,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3084,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3085,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3085,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3086,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3086,2,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
3086,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3086,4,Dysphemia,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
3086,5,Headache,Headaches NEC,Headaches,Nerv,N
3086,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3086,7,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3087,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3088,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3088,2,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
3088,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3088,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3088,5,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3088,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3088,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3088,8,Weight bearing difficulty,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3089,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3090,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3090,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3090,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3091,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3091,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3091,3,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
3092,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3092,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
3092,3,Lactose intolerance,Sugar intolerance (excl glucose intolerance),Food intolerance syndromes,Metab,N
3092,4,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
3092,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
3093,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3094,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3094,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3095,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
3095,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3096,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3096,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
3096,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
3096,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3096,5,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3096,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3097,1,Calcinosis,Trophic disorders,Tissue disorders NEC,Genrl,N
3097,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
3097,3,Extremity necrosis,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3097,4,Penile necrosis,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3097,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3098,1,Brain stem haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3099,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3100,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3101,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3102,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3102,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3103,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3104,1,Contraindication to medical treatment,Social issues NEC,Lifestyle issues,SocCi,N
3104,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3104,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
3105,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3105,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3106,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
3107,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3108,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3108,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3109,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3109,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
3109,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3109,4,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
3110,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3110,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3110,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3111,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3112,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3112,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3113,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3113,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3114,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3114,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3115,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3115,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3116,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3116,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3117,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3117,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3118,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3118,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3118,3,Muscle twitching,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3118,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3118,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3119,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3119,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3119,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3120,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3120,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3120,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3120,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3121,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3121,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3121,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
3121,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3122,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
3122,2,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
3122,3,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3122,4,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3122,5,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3122,6,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3122,7,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3122,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3122,9,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3122,10,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3122,11,Inflammatory pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3122,12,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
3122,13,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3122,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3122,15,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3122,16,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3122,17,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
3123,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3124,1,Headache,Headaches NEC,Headaches,Nerv,N
3124,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3125,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3125,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3126,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3126,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3127,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
3128,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3128,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3128,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3128,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3129,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
3130,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3131,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3132,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3133,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3133,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3133,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3134,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3134,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3134,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3134,4,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
3135,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3135,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3136,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3136,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3137,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3137,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3138,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3138,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3138,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3139,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3139,2,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
3139,3,Atheroembolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3139,4,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3139,5,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3139,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3139,7,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
3139,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3140,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3140,2,Embolic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3141,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3141,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3141,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3142,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3142,2,Atheroembolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3142,3,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3142,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3142,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3142,6,Livedo reticularis,Skin vasomotor conditions,Skin vascular abnormalities,Skin,N
3142,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3143,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3144,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3144,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3144,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3144,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3145,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3145,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3145,3,Product taste abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3146,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3147,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3148,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3148,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3149,1,Aortic aneurysm rupture,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,Y
3150,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3151,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3151,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3151,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3152,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3153,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3153,2,Headache,Headaches NEC,Headaches,Nerv,N
3153,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3153,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3153,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3153,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3153,7,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3153,8,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3153,9,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3153,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3154,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3154,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3154,3,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
3155,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3156,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3156,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
3156,3,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
3156,4,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3156,5,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3156,6,Fat necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
3156,7,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3156,8,Induration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3156,9,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3156,10,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
3156,11,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3156,12,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3156,13,Wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
3157,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
3157,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3157,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3158,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3158,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3159,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
3159,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3159,3,Headache,Headaches NEC,Headaches,Nerv,N
3159,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3160,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3161,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
3162,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3162,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3162,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
3163,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3164,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3164,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3164,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3165,1,Exophthalmos,"Structural change, deposit and degeneration of eye NEC","Ocular structural change, deposit and degeneration NEC",Eye,N
3165,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
3165,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3165,4,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3166,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3166,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3166,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3167,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3167,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3167,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3168,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3168,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3169,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3169,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3170,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
3171,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3171,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3172,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3173,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3173,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3173,3,Pelvic haemorrhage,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
3173,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3173,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3174,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3175,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3176,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3177,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3177,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3177,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3177,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3177,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3178,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3178,2,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
3178,3,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3178,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3178,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3179,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
3179,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3180,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3181,1,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,Y
3182,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3182,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3183,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3183,2,Headache,Headaches NEC,Headaches,Nerv,N
3184,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3184,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3185,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3185,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3186,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3187,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3187,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3187,3,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3187,4,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
3187,5,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
3187,6,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3187,7,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3187,8,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
3188,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3188,2,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3188,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3189,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3189,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3190,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3191,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3191,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3191,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3191,4,Headache,Headaches NEC,Headaches,Nerv,N
3191,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3191,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3192,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3192,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3192,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3192,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3193,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
3194,1,Asthenopia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
3194,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
3194,3,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3194,4,Headache,Headaches NEC,Headaches,Nerv,N
3194,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
3194,6,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
3195,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
3195,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3195,3,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
3195,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3196,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3196,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3196,3,Lip haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
3197,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3197,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3197,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3198,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3199,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3199,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3199,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
3199,4,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3199,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3200,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3201,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3202,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3203,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3204,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3205,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3205,2,Tachyarrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3206,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3207,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3207,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3207,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3208,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3208,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3208,3,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3208,4,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3208,5,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3208,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3209,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3209,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3210,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3210,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3210,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3211,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3212,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3212,2,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3212,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3212,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3212,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3213,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3214,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3214,2,Erosive duodenitis,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3214,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3214,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3214,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3215,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3216,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3216,2,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3217,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3217,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3217,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3218,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3218,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3218,3,Headache,Headaches NEC,Headaches,Nerv,N
3218,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3218,5,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3219,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3219,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
3219,3,Shock haemorrhagic,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3220,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3220,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3221,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
3221,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
3221,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
3221,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3222,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3223,1,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3223,2,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
3224,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3224,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3224,3,Peripheral nerve palsy,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3225,1,Affective disorder,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
3225,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3225,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3225,4,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3225,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3225,6,Pharyngeal haemorrhage,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
3225,7,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
3225,8,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3225,9,Tongue haemorrhage,Tongue disorders,Tongue conditions,Gastr,N
3226,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3226,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3226,3,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3226,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3227,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3227,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3227,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3228,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3228,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3229,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3229,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3229,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3229,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3230,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3230,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3231,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3231,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3231,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3231,4,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
3231,5,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3232,1,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3232,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3233,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3234,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
3235,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3236,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3236,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3236,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3236,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3237,1,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
3238,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3238,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3239,1,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3239,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3240,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3240,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3240,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3240,4,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
3240,5,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
3241,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3242,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3242,2,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
3243,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3244,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
3245,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3245,2,Headache,Headaches NEC,Headaches,Nerv,N
3245,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3246,1,Concomitant disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
3246,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3246,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3246,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3247,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3247,2,Headache,Headaches NEC,Headaches,Nerv,N
3248,1,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
3248,2,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
3248,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3249,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3249,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3249,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
3250,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3250,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3250,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3250,4,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
3251,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3252,1,Thalamus haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3253,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3254,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3255,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3255,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3256,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3256,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3257,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3257,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3258,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3259,1,Vascular pseudoaneurysm,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3260,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3260,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3260,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3260,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3261,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3261,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3261,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3262,1,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
3263,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3264,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3264,2,Haemorrhagic hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3264,3,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
3265,1,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3265,2,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3265,3,Haemorrhagic hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3265,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3265,5,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
3266,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3266,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3266,3,Headache,Headaches NEC,Headaches,Nerv,N
3267,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3268,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3269,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3270,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3271,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3271,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3271,3,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3272,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
3272,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
3273,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
3273,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
3274,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
3274,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3274,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3275,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3275,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3275,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3276,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3276,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3277,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3277,2,Haemorrhagic hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3277,3,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
3278,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3278,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3278,3,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
3278,4,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3278,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3278,6,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3278,7,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
3278,8,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3278,9,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3278,10,Oliguria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3278,11,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3278,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3278,13,Palmar erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3278,14,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3278,15,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3278,16,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3278,17,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3278,18,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3278,19,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3278,20,Urine odour abnormal,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3279,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3279,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3280,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3280,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3280,3,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
3281,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3281,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3282,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3282,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3282,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3283,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3283,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
3284,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3284,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3284,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3284,4,Haemorrhage urinary tract,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
3284,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3285,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
3285,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
3285,3,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3285,4,Muscle contracture,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3285,5,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,Y
3286,1,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
3287,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3287,2,Gastroduodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3287,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3287,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3287,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3287,6,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3288,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3288,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3289,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3289,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
3289,3,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3289,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3289,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3289,6,Joint effusion,Joint related signs and symptoms,Joint disorders,Musc,N
3289,7,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3289,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3289,9,Polyarthritis,Arthropathies NEC,Joint disorders,Musc,N
3289,10,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3289,11,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3290,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3290,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3290,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3290,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3290,5,Joint effusion,Joint related signs and symptoms,Joint disorders,Musc,N
3290,6,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3290,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3290,8,Polyarthritis,Arthropathies NEC,Joint disorders,Musc,N
3290,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3290,10,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3291,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3292,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3292,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3293,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3293,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3294,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3295,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3295,2,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3296,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3296,2,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3297,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3297,2,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3298,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3298,2,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3299,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3299,2,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3300,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3300,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3301,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3301,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3302,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3302,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3302,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3302,4,Headache,Headaches NEC,Headaches,Nerv,N
3302,5,Nystagmus,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3302,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3303,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3304,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3305,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3305,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3306,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3306,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3306,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3306,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3307,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3307,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3308,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3308,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
3309,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3310,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3310,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3311,1,Gastritis haemorrhagic,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,Y
3311,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3312,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3313,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3313,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3313,3,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3314,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3314,2,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3315,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3315,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3315,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3316,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3316,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3316,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3316,4,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3316,5,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
3317,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3318,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3319,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
3319,2,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
3320,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3321,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3322,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3322,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3322,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3323,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3323,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3323,3,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
3323,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3323,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
3323,6,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
3324,1,Post thrombotic syndrome,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3325,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3326,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3326,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3326,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3326,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3327,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3327,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3327,3,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
3327,4,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
3327,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3327,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3327,7,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3327,8,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
3327,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3328,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3329,1,Open angle glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
3330,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3331,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3332,1,Haemorrhagic hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
3333,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3334,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3335,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3336,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3337,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3337,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3337,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3338,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3338,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3339,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3339,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3340,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3340,2,Epidermal necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3340,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3340,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3341,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3341,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3342,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3342,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3342,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3342,4,Kidney fibrosis,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
3342,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3342,6,Renal tubular atrophy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
3342,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3342,8,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3342,9,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3343,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3344,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3344,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3345,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3346,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3346,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3347,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3347,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3347,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3348,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3348,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3349,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
3349,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
3349,3,Hepatitis chronic active,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
3349,4,Spontaneous haemorrhage,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,Y
3350,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3351,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3351,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3352,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3352,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3353,1,Peritoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3354,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3355,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3355,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3356,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3356,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3357,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3357,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3358,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3358,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3358,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3358,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3359,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3359,2,Epidermal necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3359,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3360,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
3361,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3362,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3362,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3363,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3364,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3365,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3366,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3367,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3368,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3368,2,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3368,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
3369,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3369,2,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3369,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
3370,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3370,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3371,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3372,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3373,1,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
3373,2,Headache,Headaches NEC,Headaches,Nerv,N
3373,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3374,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3375,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3375,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3376,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3376,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3376,3,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3376,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3377,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3377,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3377,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3378,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3378,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3379,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
3380,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3380,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3380,3,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
3380,4,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3380,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3380,6,Lip discolouration,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
3380,7,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
3381,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3381,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3382,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3383,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3383,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3384,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3385,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3386,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3386,2,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3386,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3387,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3387,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3387,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3387,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
3387,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3387,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3388,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3388,2,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3389,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
3389,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3389,3,Obsessive-compulsive disorder,Obsessive-compulsive disorders and symptoms,Anxiety disorders and symptoms,Psych,N
3389,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
3390,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3390,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3391,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3391,2,Haemoperitoneum,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3391,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3391,4,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3392,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3392,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3393,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3394,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3394,2,Contraindication to medical treatment,Social issues NEC,Lifestyle issues,SocCi,N
3394,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3395,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3396,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3396,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3396,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3396,4,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3396,5,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3396,6,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
3396,7,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3396,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3397,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3397,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3398,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3399,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3400,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3401,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
3401,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3402,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3403,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3404,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3404,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3404,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3405,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3406,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3407,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3408,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3409,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3410,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3410,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
3411,1,Cardio-respiratory arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3411,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3411,3,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3411,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3411,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3412,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3412,2,Product lot number issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3413,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3413,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3414,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3414,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3415,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3415,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3416,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3416,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3416,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3416,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
3416,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3416,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3417,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3418,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3418,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3418,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3419,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3419,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3419,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3420,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3421,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3421,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3421,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3422,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3422,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3422,3,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3422,4,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3422,5,Soft tissue haemorrhage,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3423,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3423,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3423,3,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3423,4,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3423,5,Soft tissue haemorrhage,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3424,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3424,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3424,3,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3424,4,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3424,5,Soft tissue haemorrhage,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3425,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3426,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3426,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3426,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3427,1,Headache,Headaches NEC,Headaches,Nerv,N
3427,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3427,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3428,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3429,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3430,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3431,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3432,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3433,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3433,2,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3434,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3435,1,Anal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3435,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3436,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3436,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3437,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3437,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3438,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3439,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
3439,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3439,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3439,4,Muscle rupture,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
3439,5,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3440,1,Gastrointestinal ulcer haemorrhage,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
3441,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
3441,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3441,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3441,4,Muscle rupture,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
3441,5,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3442,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
3442,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3442,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3442,4,Muscle rupture,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
3442,5,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3443,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3444,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3445,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3445,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3446,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3446,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3447,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3447,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3447,3,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3447,4,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3447,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3447,6,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3447,7,Headache,Headaches NEC,Headaches,Nerv,N
3447,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3447,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3448,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3448,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3449,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3449,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3449,3,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3449,4,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3449,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3449,6,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3449,7,Headache,Headaches NEC,Headaches,Nerv,N
3449,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3449,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3450,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3450,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3450,3,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3450,4,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3450,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3450,6,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3450,7,Headache,Headaches NEC,Headaches,Nerv,N
3450,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3450,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3451,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3451,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3451,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3452,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3452,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3452,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3452,4,Headache,Headaches NEC,Headaches,Nerv,N
3452,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3453,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3453,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3454,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3454,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3454,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3455,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3456,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3456,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3456,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3456,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3456,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3457,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3457,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3457,3,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3457,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3457,5,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3457,6,Headache,Headaches NEC,Headaches,Nerv,N
3457,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3458,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3459,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3459,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3460,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
3460,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3460,3,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3461,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3461,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3461,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3461,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3461,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3462,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3462,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3462,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3462,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3462,5,Joint effusion,Joint related signs and symptoms,Joint disorders,Musc,N
3463,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
3463,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3464,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3464,2,Normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3464,3,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3464,4,Wound infection pseudomonas,Pseudomonal infections,Bacterial infectious disorders,Infec,N
3465,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
3465,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
3465,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3465,4,Normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3465,5,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3465,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3465,7,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
3466,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
3466,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3466,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3466,4,Normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3466,5,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3466,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3466,7,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,Y
3467,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
3467,2,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
3467,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3467,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3467,5,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3468,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3468,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3468,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3468,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3468,5,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
3468,6,Headache,Headaches NEC,Headaches,Nerv,N
3468,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3468,8,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
3469,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3470,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,Y
3471,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3471,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3471,3,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
3472,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3473,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3473,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3474,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3474,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
3475,1,Abdominal compartment syndrome,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
3475,2,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,Y
3476,1,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
3477,1,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
3477,2,Urinary sediment present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
3478,1,Anaemia neonatal,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3478,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3478,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
3478,4,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
3478,5,Foetal-maternal haemorrhage,Foetal complications NEC,Foetal complications,Preg,N
3478,6,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
3479,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3480,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
3480,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
3481,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3482,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3483,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
3483,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3483,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3483,4,Normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3483,5,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3483,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3484,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3484,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3484,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3484,4,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
3484,5,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3485,1,Breast haematoma,Breast signs and symptoms,Breast disorders,Repro,N
3485,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3485,3,Urinary bladder haemorrhage,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
3486,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3487,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
3487,2,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3487,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3488,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3488,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3488,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3488,4,Headache,Headaches NEC,Headaches,Nerv,N
3488,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3489,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3490,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3490,2,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3490,3,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
3491,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3491,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3491,3,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3491,4,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3492,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3492,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3492,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3492,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3493,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3494,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
3494,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
3494,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
3495,1,Catheter site haemorrhage,Implant and catheter site reactions,Administration site reactions,Genrl,N
3495,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3496,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3496,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3497,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3497,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3498,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3498,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3498,3,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3498,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3499,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3499,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3499,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3500,1,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
3500,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3501,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3502,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3503,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3504,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3504,2,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
3505,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3505,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3505,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3505,4,Oesophageal haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3506,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3507,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3508,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3508,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3508,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3508,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3509,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3510,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3511,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3511,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3512,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
3512,2,Epigastric discomfort,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
3512,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3512,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3512,5,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
3512,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3513,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3514,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3514,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3514,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3514,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3515,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3516,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3516,2,Faeces soft,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3516,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3516,4,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
3517,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3518,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3519,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3520,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3521,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3521,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3522,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3523,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3523,2,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
3523,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3523,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3523,5,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3524,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3525,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3526,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3527,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3527,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3527,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,Y
3528,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3528,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
3529,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3529,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3530,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3530,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3531,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3531,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3532,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3532,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3533,1,Headache,Headaches NEC,Headaches,Nerv,N
3533,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3534,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3534,2,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3534,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3535,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3535,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3535,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3535,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3535,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3536,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3536,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3537,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3537,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3537,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3537,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3538,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3538,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3539,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3540,1,Genital rash,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
3540,2,Penile erythema,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,3,Penile exfoliation,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,4,Penile haemorrhage,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,5,Penile pain,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,6,Penile swelling,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,7,Penile vein thrombosis,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
3540,8,Postoperative wound complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3540,9,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3540,10,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3541,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3542,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3542,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3542,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3542,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3543,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3543,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
3544,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
3545,1,Acne,Acnes,Skin appendage conditions,Skin,N
3545,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3545,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3545,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3546,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3546,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3547,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3548,1,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
3548,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3549,1,Anticoagulation drug level abnormal,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3549,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3550,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3551,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3551,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3552,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3553,1,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
3553,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3553,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3553,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
3554,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3555,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3555,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3555,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3555,4,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3555,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3556,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
3556,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3556,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3556,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3557,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3558,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3558,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3558,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3558,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3559,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3560,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3560,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3560,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3560,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3560,5,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3560,6,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3560,7,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3560,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3560,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3560,10,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3560,11,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3560,12,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3560,13,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
3561,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3562,1,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3562,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3563,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3564,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3564,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3565,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3566,1,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3566,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3566,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3566,4,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3566,5,Headache,Headaches NEC,Headaches,Nerv,N
3566,6,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3566,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3567,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
3567,2,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3567,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3567,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3567,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3567,6,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3568,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3568,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3569,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3570,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3571,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3571,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3571,3,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3571,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3571,5,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3572,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3572,2,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
3572,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3572,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3572,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3573,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3573,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3574,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3575,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3575,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3576,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3576,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3577,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3578,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3579,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
3579,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3579,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3579,4,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
3579,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3579,6,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
3580,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3580,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3580,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3581,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3581,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3581,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
3582,1,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3583,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3583,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3583,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3583,4,Headache,Headaches NEC,Headaches,Nerv,N
3583,5,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3583,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3583,7,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3583,8,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3584,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3584,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3584,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3585,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3586,1,Cerebral venous sinus thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
3586,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3586,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3586,4,Extensor plantar response,Abnormal reflexes,Neurological disorders NEC,Nerv,N
3586,5,Headache,Headaches NEC,Headaches,Nerv,N
3586,6,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3586,7,Intracranial haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3586,8,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3587,1,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3587,2,Cerebellar haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3588,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3588,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3588,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3588,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
3588,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3588,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3588,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3589,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3589,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3589,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3589,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3589,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3590,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3591,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3591,2,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3591,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3591,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3592,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3593,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3594,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3595,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3595,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3595,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3595,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3595,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3596,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3596,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3597,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3597,2,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3597,3,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
3597,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3597,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3598,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3599,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
3599,2,Headache,Headaches NEC,Headaches,Nerv,N
3600,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3600,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3600,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3600,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3600,5,Large intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3600,6,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3601,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3601,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3602,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3602,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3602,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3603,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3603,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3604,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3604,2,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3604,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3604,4,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3604,5,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
3604,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
3604,7,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3604,8,Oral herpes,Herpes viral infections,Viral infectious disorders,Infec,N
3604,9,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
3604,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3604,11,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
3605,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3605,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3606,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3606,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3607,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
3608,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3608,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3608,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3608,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3608,5,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3608,6,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3609,1,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3609,2,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
3609,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3610,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
3611,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3611,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3611,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3611,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3611,5,Product monitoring error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3612,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3612,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3613,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3613,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3614,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3614,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3614,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3615,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3616,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3616,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3617,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3617,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3618,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3618,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3618,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
3618,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3619,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3619,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3620,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3621,1,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
3622,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3622,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3622,3,Tongue haemorrhage,Tongue disorders,Tongue conditions,Gastr,N
3623,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3623,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3623,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3624,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3624,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3625,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
3626,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3626,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3627,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3627,2,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3627,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3628,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3628,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3629,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3630,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3630,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3631,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3632,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
3632,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3632,3,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3633,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3633,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
3634,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
3635,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3635,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3636,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3636,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3636,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3637,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3637,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3638,1,Maternal exposure during delivery,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
3638,2,Pelvic haematoma obstetric,Maternal complications of delivery NEC,Maternal complications of labour and delivery,Preg,N
3639,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3639,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3639,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3640,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3641,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3641,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3641,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3642,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
3642,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3643,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3644,1,Chest wall haematoma,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3644,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3644,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3644,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3645,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3646,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3646,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3646,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3646,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3646,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3646,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3646,7,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3646,8,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3646,9,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
3646,10,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3646,11,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3646,12,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3646,13,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3647,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3647,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3647,3,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
3647,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
3648,1,Blood pressure systolic decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3648,2,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
3648,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3648,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3649,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3650,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3650,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3650,3,Migraine,Migraine headaches,Headaches,Nerv,N
3651,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3652,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3653,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3653,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3654,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3654,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3654,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3654,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3654,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3655,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3655,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3656,1,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
3657,1,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3658,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3658,2,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
3658,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3658,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
3659,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3660,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3660,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3661,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3661,2,Prosthetic cardiac valve thrombosis,Cardiac complications associated with device,Complications associated with device,Genrl,N
3661,3,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
3662,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3662,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3662,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3662,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3663,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3664,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3664,2,Duodenitis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
3664,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3664,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3664,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3664,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3664,7,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3664,8,Microcytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3665,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3665,2,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
3665,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3665,4,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3665,5,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3665,6,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
3665,7,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
3666,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3666,2,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3667,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3667,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3668,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3668,2,Lower urinary tract symptoms,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3668,3,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3669,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3670,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3670,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3671,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3671,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3672,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3672,2,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
3672,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3672,4,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3672,5,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3673,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3673,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3673,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3673,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3674,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
3675,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3676,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3676,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3677,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3678,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3679,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3679,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3680,1,Basal ganglia haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3681,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3682,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3682,2,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
3682,3,Deafness,Hearing losses,Hearing disorders,Ear,N
3682,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3682,5,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
3682,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3682,7,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3682,8,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3682,9,Feeling drunk,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3682,10,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3682,11,Hair disorder,Pilar disorders NEC,Skin appendage conditions,Skin,N
3682,12,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3682,13,Meniere's disease,Inner ear disorders NEC,Inner ear and VIIIth cranial nerve disorders,Ear,N
3682,14,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
3682,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3682,16,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
3683,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3684,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3684,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3685,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3685,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3685,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3686,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3686,2,Urinary bladder haemorrhage,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
3687,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3687,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3688,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3688,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3688,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3688,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
3688,5,Urine odour abnormal,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3689,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3690,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3691,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3691,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3692,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3692,2,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
3692,3,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
3693,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3693,2,Aspiration joint,Musculoskeletal and soft tissue histopathology procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
3693,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3693,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3693,5,Headache,Headaches NEC,Headaches,Nerv,N
3693,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3693,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3693,8,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
3693,9,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3693,10,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3694,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3694,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3695,1,Subarachnoid haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3696,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3696,2,Headache,Headaches NEC,Headaches,Nerv,N
3696,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3697,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3697,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3697,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3698,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3699,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
3699,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3699,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3699,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3700,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3701,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3702,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3702,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3702,3,Headache,Headaches NEC,Headaches,Nerv,N
3703,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3703,2,Bladder disorder,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
3703,3,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
3703,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3703,5,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3703,6,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3703,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3703,8,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3703,9,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
3704,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3705,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3705,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3706,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3706,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3707,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3707,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3708,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
3708,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3708,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3708,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3708,5,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3709,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3709,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
3709,3,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3710,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3710,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3711,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3711,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3712,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3713,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3713,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3714,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3714,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3714,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3714,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
3715,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3715,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3715,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3715,4,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3715,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3715,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3716,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3716,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3716,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3716,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
3716,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3717,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3717,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3717,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3717,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3717,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3718,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3718,2,Haemorrhagic ovarian cyst,Ovarian and fallopian tube cysts and neoplasms,Ovarian and fallopian tube disorders,Repro,N
3718,3,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
3718,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3719,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
3719,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3719,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3719,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3719,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3719,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
3720,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3721,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3721,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3722,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3722,2,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
3722,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3722,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3722,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3722,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3722,7,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
3722,8,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3722,9,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3723,1,Basal ganglia infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3723,2,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
3723,3,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3723,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3723,5,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3723,6,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3723,7,Facial paresis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
3723,8,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3723,9,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3723,10,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
3723,11,Thalamus haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3724,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3725,1,Stoma site haemorrhage,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
3726,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3726,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3726,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3727,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3727,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3728,1,Coagulation time shortened,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3728,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3728,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3729,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3729,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3729,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3730,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3730,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3730,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3731,1,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3732,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3732,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
3733,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3733,2,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
3734,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3734,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3734,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3734,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3735,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3736,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3736,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3737,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3738,1,Haemorrhage subcutaneous,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3738,2,International normalised ratio,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3739,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3739,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3739,3,Hypoperfusion,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3740,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3741,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3741,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3742,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
3742,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
3743,1,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3744,1,Headache,Headaches NEC,Headaches,Nerv,N
3744,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3745,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3745,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3745,3,Headache,Headaches NEC,Headaches,Nerv,N
3746,1,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3747,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
3748,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3748,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3749,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3749,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3750,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3751,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3752,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3752,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3752,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3752,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3752,5,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,Y
3752,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3753,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3753,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3753,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
3753,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3753,5,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3753,6,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3754,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3755,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3755,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3755,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3756,1,Thalamus haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3757,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3758,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
3758,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3758,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3758,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3759,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
3759,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3759,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3759,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3760,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3761,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3761,2,Ear haemorrhage,Ear disorders NEC,Aural disorders NEC,Ear,N
3761,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3761,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3762,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3763,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3764,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
3764,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
3764,3,Open angle glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
3765,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3766,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3766,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3767,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3767,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3768,1,Stoma site haemorrhage,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
3769,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3769,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3769,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3770,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
3770,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3771,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3771,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3772,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
3772,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3773,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3774,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3775,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3775,2,Adrenocortical insufficiency acute,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
3776,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3777,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3778,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3778,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3779,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3779,2,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3780,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3780,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
3781,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
3782,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3782,2,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
3782,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3783,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3783,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3784,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3784,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3784,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3785,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3785,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3786,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3786,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3787,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3788,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3788,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3789,1,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
3790,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3791,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3791,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3791,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3792,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3792,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3793,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3793,2,Transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
3794,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
3794,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3794,3,Colon cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
3794,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3794,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3795,1,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
3796,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3797,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
3797,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3798,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
3798,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3798,3,Muscle contractions involuntary,Neuromuscular disorders NEC,Neuromuscular disorders,Nerv,N
3799,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3799,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3800,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3800,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3801,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3801,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3801,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3802,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3802,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3803,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3803,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3804,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3805,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3805,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3806,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3807,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3808,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3808,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3809,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
3809,2,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
3809,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
3809,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3809,5,Open angle glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
3810,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
3810,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
3810,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3810,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3810,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3811,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3811,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3811,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3811,4,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3811,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3811,6,Embolism venous,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3811,7,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
3811,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3811,9,Splenic infarction,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
3811,10,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3811,11,Visual field defect,Visual field disorders,Vision disorders,Eye,N
3812,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3813,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3813,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3813,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
3814,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3814,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3815,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3816,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3816,2,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3816,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3816,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
3817,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3818,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3818,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3818,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3818,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3819,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3819,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
3819,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
3819,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3819,5,Dyspnoea at rest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3819,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3819,7,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3819,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3819,9,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3819,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3819,11,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
3819,12,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
3819,13,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3819,14,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3819,15,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
3820,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3821,1,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3821,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3822,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3823,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3823,2,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
3824,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3824,2,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
3825,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3826,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3826,2,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
3827,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
3827,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3827,3,Decreased immune responsiveness,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
3827,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3827,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3827,6,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3827,7,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3827,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3828,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3829,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3830,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3830,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3830,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3831,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3831,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3832,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3832,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3833,1,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3834,1,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
3834,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3834,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3834,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3834,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
3834,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3835,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3836,1,Accelerated hypertension,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
3836,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3836,3,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3836,4,Traumatic intracranial haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3837,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3837,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3837,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3837,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3838,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3838,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3838,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3838,4,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
3839,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3840,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3841,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3841,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3841,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3842,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3843,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3844,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3844,2,Headache,Headaches NEC,Headaches,Nerv,N
3844,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3844,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3844,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3844,6,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3845,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3845,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3846,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3846,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
3846,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3846,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3847,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3848,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3849,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3850,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3850,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3850,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
3851,1,Traumatic intracranial haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3852,1,Butterfly rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3852,2,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
3852,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3853,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3854,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3854,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3854,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3854,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3855,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3855,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3856,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3856,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3856,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3857,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3857,2,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
3857,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3858,1,Multiple fractures,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
3859,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3860,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3861,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3862,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3862,2,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
3862,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
3863,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3863,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3863,3,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
3863,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3863,5,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3863,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3864,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
3864,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3864,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3865,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3865,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3866,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3867,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3868,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
3869,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3870,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3870,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3871,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3872,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3873,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3874,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,Y
3874,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3874,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3875,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3875,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3875,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3875,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3875,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3875,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3875,7,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3875,8,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3875,9,Transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
3876,1,Breast necrosis,Breast disorders NEC,Breast disorders,Repro,N
3877,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3878,1,Vascular pseudoaneurysm,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
3879,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3880,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3881,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3882,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
3883,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3883,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,Y
3884,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3884,2,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3884,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3885,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
3886,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3887,1,Coma scale abnormal,Neurologic diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
3887,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3888,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3889,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3890,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3890,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3891,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3891,2,Headache,Headaches NEC,Headaches,Nerv,N
3891,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3891,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3891,5,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3892,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3892,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3892,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
3892,4,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3893,1,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3893,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3893,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3894,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3895,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3895,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3895,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3896,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
3896,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3896,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3896,4,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
3896,5,Pelvic cyst,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
3896,6,Peripheral artery thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3896,7,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3897,1,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
3897,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3898,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3898,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
3899,1,Migraine,Migraine headaches,Headaches,Nerv,N
3900,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3901,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3901,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3901,3,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3901,4,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
3901,5,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
3901,6,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3901,7,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
3902,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3903,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
3903,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
3904,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3904,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3905,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
3906,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3907,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3907,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
3907,3,Primary adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
3907,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3907,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3908,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3908,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
3909,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3909,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3910,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3910,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
3910,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3911,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3912,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3912,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3912,3,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
3913,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3913,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3914,1,Abdominal wall haemorrhage,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,Y
3915,1,Brain stem stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3915,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3915,3,Pulmonary valve incompetence,Pulmonary valvular disorders,Cardiac valve disorders,Card,N
3915,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
3915,5,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3916,1,Brain stem infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3916,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3916,3,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
3916,4,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3917,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3918,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3919,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3920,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3920,2,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
3920,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
3920,4,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3921,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3921,2,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
3921,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3922,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
3923,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
3923,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3923,3,Headache,Headaches NEC,Headaches,Nerv,N
3923,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3923,5,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
3923,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
3924,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
3925,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3925,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3925,3,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3926,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
3926,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,Y
3927,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3927,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
3927,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3928,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3928,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3928,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3929,1,Food allergy,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
3930,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3931,1,Headache,Headaches NEC,Headaches,Nerv,N
3931,2,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
3931,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3931,4,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3932,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3932,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3932,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3933,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3934,1,Intra-abdominal haematoma,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3935,1,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3935,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3935,3,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
3936,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3936,2,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3936,3,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3936,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3937,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3937,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3938,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3938,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3938,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3939,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3939,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3939,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3940,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3940,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3941,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3942,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3942,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3943,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3943,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3943,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
3943,4,Product packaging confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3944,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3945,1,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3945,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
3945,3,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3946,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3946,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3946,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3947,1,Aortic valve replacement,Cardiac valve therapeutic procedures,Cardiac therapeutic procedures,Surg,N
3947,2,Traumatic haemothorax,Chest and respiratory tract injuries NEC,Injuries NEC,Inj&P,N
3948,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3948,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3949,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3949,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3949,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3950,1,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
3951,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3951,2,Headache,Headaches NEC,Headaches,Nerv,N
3951,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3951,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3952,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3952,2,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
3952,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3953,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3954,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3954,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3955,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3955,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3956,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3956,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3956,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3957,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3958,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3958,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3958,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3958,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3958,5,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3958,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3959,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3960,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
3960,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
3960,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
3960,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
3961,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3962,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3962,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3963,1,Leiomyosarcoma,Leiomyosarcomas,Soft tissue neoplasms malignant and unspecified,Neopl,N
3964,1,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3964,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3965,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3966,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3966,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3967,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3967,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3967,3,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3967,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3967,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3968,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
3968,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3968,3,Immunoglobulins increased,Immunoglobulin analyses,Immunology and allergy investigations,Inv,N
3968,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3969,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3970,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
3971,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3971,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3972,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3973,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3973,2,Pancreatic mass,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
3973,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3974,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
3974,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3975,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3975,2,Pneumonia aspiration,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
3975,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3975,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
3976,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
3976,2,Breath odour,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3976,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
3976,4,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
3977,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3978,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
3978,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3979,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3979,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3980,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3980,2,Pancreatic haemorrhage,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
3980,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3981,1,Haemorrhoidal haemorrhage,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
3982,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3983,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3984,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
3984,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
3984,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
3985,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
3985,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3985,3,Oesophageal ulcer haemorrhage,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
3985,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
3986,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3986,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3987,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3988,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
3988,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3989,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3990,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3991,1,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
3992,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
3992,2,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
3993,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3994,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3994,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
3994,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
3994,4,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3994,5,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
3994,6,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3995,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
3995,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
3996,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3996,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3996,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
3996,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3996,5,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3997,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3998,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
3999,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4000,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4001,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4002,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4002,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4002,3,Occult blood positive,Faecal analyses NEC,Gastrointestinal investigations,Inv,N
4002,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4003,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4003,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
4004,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4004,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
4005,1,Thalamus haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4006,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4006,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4007,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4008,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4008,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4009,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4009,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4010,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4010,2,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4011,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4011,2,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4012,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4012,2,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
4012,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4012,4,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4012,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4012,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4012,7,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
4013,1,Atrial flutter,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4013,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4014,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4015,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4015,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
4015,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4015,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4015,5,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
4015,6,Subcapsular renal haematoma,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
4015,7,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4016,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4017,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4017,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4018,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4019,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4019,2,Joint effusion,Joint related signs and symptoms,Joint disorders,Musc,N
4020,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4020,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4020,3,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
4020,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4021,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4021,2,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
4021,3,Post procedural pulmonary embolism,Respiratory tract and thoracic cavity procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4022,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4022,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4023,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4024,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
4024,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4025,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4025,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4026,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4027,1,Helicobacter infection,Helicobacter infections,Bacterial infectious disorders,Infec,N
4027,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4028,1,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4028,2,Herbal interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4028,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4029,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4029,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4030,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4030,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4030,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4030,4,Product packaging confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4031,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4031,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4031,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4031,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4031,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4032,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4032,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4032,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4033,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
4033,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4034,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4035,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4035,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4036,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4036,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4037,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4037,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4038,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4038,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4039,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4040,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4040,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4041,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4041,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4042,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4043,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
4044,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4045,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4045,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4045,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4045,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4046,1,Headache,Headaches NEC,Headaches,Nerv,N
4046,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4046,3,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
4046,4,Spontaneous haemorrhage,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4047,1,Plicated tongue,Tongue disorders,Tongue conditions,Gastr,N
4047,2,Tongue oedema,Tongue signs and symptoms,Tongue conditions,Gastr,N
4048,1,Headache,Headaches NEC,Headaches,Nerv,N
4048,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4048,3,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
4048,4,Spontaneous haemorrhage,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4048,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4049,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4050,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4050,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4051,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4051,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4051,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4052,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4053,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4053,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4054,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4054,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4055,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4055,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4056,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
4056,2,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4057,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4057,2,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4057,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4058,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4059,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4059,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4060,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4060,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4061,1,Lacunar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4062,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4062,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4063,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4064,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4065,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
4065,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4065,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
4066,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4066,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4067,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4068,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4068,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4068,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4068,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4069,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4070,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4070,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4070,3,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4070,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4070,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4070,6,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4071,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4071,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4072,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4072,2,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,Y
4072,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4073,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4074,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4075,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4075,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4075,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4076,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4076,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4076,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4076,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4077,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4077,2,Disorganised speech,Speech and language usage disturbances,Communication disorders and disturbances,Psych,N
4077,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4077,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4078,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4078,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4079,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4079,2,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
4080,1,Haematospermia,Spermatogenesis and semen disorders,Sexual function and fertility disorders,Repro,N
4081,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4081,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4081,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4082,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4082,2,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4082,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4082,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4083,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4084,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
4084,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4084,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4084,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4085,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4085,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4086,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4086,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4086,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4086,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4086,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4086,6,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4086,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4086,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4086,9,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
4086,10,Headache,Headaches NEC,Headaches,Nerv,N
4086,11,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
4086,12,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
4086,13,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
4086,14,Listless,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
4086,15,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4086,16,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4086,17,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4086,18,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
4086,19,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
4087,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4087,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4088,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4088,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4089,1,Biliary sepsis,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
4089,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4089,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4089,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4090,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4090,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4090,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
4090,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4090,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4090,6,Therapeutic drug monitoring analysis not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4091,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4092,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4092,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4092,3,Pulse abnormal,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
4093,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
4094,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
4094,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4095,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4095,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4096,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4097,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4098,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4099,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4100,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4101,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4101,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4102,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4102,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4103,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4104,1,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4105,1,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
4106,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4107,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4107,2,Headache,Headaches NEC,Headaches,Nerv,N
4108,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4109,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4109,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4110,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4110,2,Prostatomegaly,"Prostatic signs, symptoms and disorders NEC",Prostatic disorders (excl infections and inflammations),Repro,N
4110,3,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
4111,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
4111,2,Maternal exposure during breast feeding,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4112,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4113,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4114,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4115,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4115,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4115,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4116,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4117,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4118,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4119,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4119,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,Y
4120,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
4121,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4121,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4122,1,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4123,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4123,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4124,1,Hypervolaemia,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
4124,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4125,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4125,2,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4126,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4126,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4126,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
4127,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4127,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4127,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4127,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4128,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4128,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4129,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4130,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4130,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4130,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4130,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4131,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4132,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4133,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4134,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4135,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4136,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4137,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4138,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4138,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4138,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4138,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
4138,5,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
4139,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4139,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4140,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4141,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4142,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4142,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4143,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4143,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4144,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4144,2,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
4144,3,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
4145,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4145,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4146,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4146,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4146,3,Headache,Headaches NEC,Headaches,Nerv,N
4147,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4148,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4149,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4150,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4150,2,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
4150,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4151,1,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
4152,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4153,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4153,2,Carotid artery occlusion,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4153,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4153,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4154,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4154,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4155,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4156,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4157,1,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
4157,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4158,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
4158,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4158,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4158,4,Headache,Headaches NEC,Headaches,Nerv,N
4158,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
4158,6,Pulseless electrical activity,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
4159,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4160,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4161,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4161,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4162,1,Factor X deficiency,Coagulation disorders congenital,Blood and lymphatic system disorders congenital,Cong,N
4162,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
4162,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4162,4,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
4162,5,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4163,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4164,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4165,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4166,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4166,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4167,1,Cutaneous vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
4167,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4168,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4169,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4170,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4170,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4171,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
4171,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4172,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4173,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4174,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4175,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4175,2,Atrial thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4175,3,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4175,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4175,5,Left atrial dilatation,Myocardial disorders NEC,Myocardial disorders,Card,N
4176,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4176,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4176,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4176,4,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4176,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4176,6,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4176,7,Hypovolaemia,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
4176,8,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4176,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4176,10,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4177,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4177,2,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4177,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4178,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4178,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4178,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4178,4,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4179,1,Anal incontinence,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4179,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4179,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4179,4,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4179,5,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4180,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4181,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4181,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4181,3,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4181,4,Corneal oedema,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
4181,5,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4181,6,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4182,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4182,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4182,3,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4182,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4182,5,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4182,6,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4182,7,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4183,1,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
4183,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4184,1,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4184,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4184,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4184,4,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4184,5,Therapeutic product effect variable,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4185,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4186,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4186,2,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4187,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4188,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4188,2,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4188,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4189,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4189,2,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4189,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4189,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4189,5,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4189,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4190,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4190,2,Angle closure glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
4190,3,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4190,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4190,5,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4190,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4191,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4192,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4193,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4194,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4195,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4196,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4197,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4197,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
4197,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
4197,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4197,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4197,6,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
4197,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
4197,8,Systemic scleroderma,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
4198,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4199,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4199,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4199,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4200,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4200,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4200,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4200,4,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
4200,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4201,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4201,2,Product monitoring error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4201,3,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4202,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4202,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4203,1,Middle cerebral artery stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4204,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4204,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4205,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4205,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4205,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4206,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4207,1,Loose tooth,Dental disorders NEC,Dental and gingival conditions,Gastr,N
4207,2,Tooth injury,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
4208,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4209,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4210,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4211,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
4211,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4211,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4212,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4212,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4212,3,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4213,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4214,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
4214,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
4214,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
4214,4,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
4215,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
4216,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4216,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4217,1,Administration site pain,Administration site reactions NEC,Administration site reactions,Genrl,N
4217,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4217,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4217,4,Colonic abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
4217,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4217,6,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
4217,7,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
4217,8,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
4217,9,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
4217,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4217,11,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
4217,12,Portal vein occlusion,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
4217,13,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4217,14,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4217,15,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4217,16,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4217,17,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4218,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4219,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4219,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4219,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4220,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4221,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4221,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4222,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4222,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4223,1,Gastrointestinal ulcer haemorrhage,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
4223,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4224,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
4225,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
4226,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4226,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4227,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4228,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4228,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4229,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4230,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4230,2,Laryngeal obstruction,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
4230,3,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
4230,4,Oesophageal haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4230,5,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
4230,6,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4230,7,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
4230,8,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4230,9,Stertor,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
4230,10,Stridor,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
4230,11,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
4230,12,Tongue discolouration,Tongue signs and symptoms,Tongue conditions,Gastr,N
4230,13,Tongue haematoma,Tongue disorders,Tongue conditions,Gastr,N
4231,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4231,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4231,3,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,Y
4231,4,Tongue haematoma,Tongue disorders,Tongue conditions,Gastr,N
4232,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4232,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4232,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4232,4,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4233,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4234,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4234,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4234,3,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4234,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
4235,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4236,1,Cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4236,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4236,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4236,4,Pituitary infarction,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
4236,5,Retinal infarction,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4237,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4237,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4238,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
4238,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4239,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4239,2,Cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4239,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4239,4,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4239,5,Pituitary haemorrhage,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
4239,6,Pituitary infarction,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
4240,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4240,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4240,3,Cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4240,4,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4240,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4240,6,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4240,7,Hypertensive crisis,Accelerated and malignant hypertension,Vascular hypertensive disorders,Vasc,N
4240,8,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
4240,9,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
4240,10,Ocular vascular disorder,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4240,11,Pituitary infarction,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
4240,12,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4240,13,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4240,14,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
4241,1,Oral mucosa haematoma,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
4241,2,Tongue haematoma,Tongue disorders,Tongue conditions,Gastr,N
4242,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4242,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4242,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4242,4,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4242,5,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
4243,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4243,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
4244,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4244,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4244,3,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4244,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
4245,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4245,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4246,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4247,1,Aortic dissection,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
4248,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4248,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4248,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4248,4,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4248,5,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
4249,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4250,1,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4251,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4252,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4252,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4253,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4254,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4254,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4254,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4255,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4255,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4255,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4256,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4256,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4257,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4257,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4257,3,Cardiac failure,Heart failures NEC,Heart failures,Card,N
4257,4,Cardiac failure,Heart failures NEC,Heart failures,Card,N
4257,5,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
4257,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4257,7,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4257,8,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
4257,9,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4257,10,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4257,11,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
4257,12,Resting tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
4257,13,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
4258,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4258,2,Azotaemia,Renal failure complications,Renal disorders (excl nephropathies),Renal,N
4258,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4259,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
4259,2,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
4259,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4260,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4261,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4262,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4263,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4264,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4265,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4266,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4267,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4268,1,Iris haemorrhage,Iris and ciliary body bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
4269,1,Iris haemorrhage,Iris and ciliary body bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
4269,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4269,3,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4270,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4270,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4270,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4271,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4272,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4273,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4274,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4275,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
4275,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
4275,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4275,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4275,5,Electrocardiogram abnormal,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
4275,6,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
4275,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4275,8,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4276,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4276,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4276,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4277,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4277,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4278,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4279,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
4279,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4279,3,Lip haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
4280,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4280,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4280,3,Oesophageal varices haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4280,4,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
4280,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4281,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
4281,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4281,3,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
4281,4,Sinus node dysfunction,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4282,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4282,2,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
4282,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4282,4,Left ventricular dilatation,Myocardial disorders NEC,Myocardial disorders,Card,N
4282,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4282,6,Sinus rhythm,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
4283,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4283,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4283,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4283,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4284,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4285,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4286,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4286,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4287,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4287,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4288,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4289,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4290,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4290,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4291,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4291,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4292,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4292,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4292,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4292,4,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
4292,5,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
4292,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4292,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4292,8,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4293,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4294,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
4294,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4294,3,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
4294,4,Dizziness postural,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4294,5,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4295,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4295,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4295,3,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
4296,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4297,1,Arteriovenous fistula site haemorrhage,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4297,2,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4297,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
4298,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4299,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4300,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4300,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4301,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
4302,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4302,2,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
4303,1,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4304,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
4304,2,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4305,1,Headache,Headaches NEC,Headaches,Nerv,N
4306,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4307,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4307,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4308,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4308,2,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4309,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4309,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4309,3,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
4310,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
4310,2,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
4311,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
4312,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4312,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4313,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4314,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4315,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4316,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4316,2,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4316,3,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4316,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4316,5,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
4317,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4318,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4318,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4318,3,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
4318,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4318,5,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4319,1,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
4320,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4320,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4321,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4321,2,Protein C decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4321,3,Protein S decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4321,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4322,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4323,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4324,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4324,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4325,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4325,2,Spinal epidural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4325,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4326,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4326,2,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4326,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4327,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4327,2,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
4327,3,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4328,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4328,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4329,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4329,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4329,3,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4329,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4329,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4329,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4330,1,Extradural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4330,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
4330,3,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4330,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
4330,5,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4330,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4330,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4330,8,Reflexes abnormal,Abnormal reflexes,Neurological disorders NEC,Nerv,N
4330,9,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
4330,10,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
4331,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
4331,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4331,3,Protein C decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4331,4,Protein S decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4331,5,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4331,6,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
4332,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4333,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
4334,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4334,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4335,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4335,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4335,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4336,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4336,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4336,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4337,1,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4337,2,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
4337,3,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
4337,4,Craniocerebral injury,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4337,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4337,6,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4337,7,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4338,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4339,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
4340,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4341,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4341,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4342,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4342,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4343,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4344,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4345,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4345,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
4345,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4345,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
4346,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4347,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4347,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4347,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4348,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
4348,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4348,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4349,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4350,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4350,2,Drug dispensed to wrong patient,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4350,3,Headache,Headaches NEC,Headaches,Nerv,N
4351,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4352,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4352,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4352,3,Uterine haemorrhage,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
4352,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4353,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4353,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4353,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4354,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4354,2,Headache,Headaches NEC,Headaches,Nerv,N
4354,3,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4354,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
4354,5,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4355,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4355,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
4356,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4357,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4357,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4357,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4357,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4358,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4358,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4358,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4359,1,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
4359,2,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4359,3,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4359,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4359,5,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4359,6,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4359,7,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
4359,8,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4359,9,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
4359,10,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
4359,11,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4359,12,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
4359,13,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
4359,14,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
4359,15,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4359,16,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4359,17,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4359,18,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4359,19,Steroid dependence,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4359,20,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4359,21,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4360,1,Retinal ischaemia,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4361,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4362,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4362,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4362,3,Uterine haemorrhage,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
4363,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4364,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4364,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4364,3,Postpartum haemorrhage,Postpartum complications NEC,Postpartum and puerperal disorders,Preg,N
4365,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4366,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
4366,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4367,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4367,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4367,3,Mallory-Weiss syndrome,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4368,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4368,2,Postpartum haemorrhage,Postpartum complications NEC,Postpartum and puerperal disorders,Preg,N
4368,3,Uterine enlargement,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
4368,4,Uterine haemorrhage,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
4368,5,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4369,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4369,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4370,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
4370,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4370,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4370,4,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
4370,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4370,6,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
4370,7,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4370,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4370,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4371,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4371,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4371,3,Hepatic vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
4371,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4372,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4372,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
4373,1,Blood electrolytes decreased,Water and electrolyte analyses NEC,"Water, electrolyte and mineral investigations",Inv,N
4373,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4373,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4373,4,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
4373,5,Nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,Y
4374,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4374,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4375,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4376,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4376,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4376,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4376,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4376,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4377,1,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4378,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4379,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4379,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4379,3,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
4380,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4381,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4382,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4383,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4384,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4385,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4386,1,Lacunar stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4387,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4388,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4388,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4389,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
4389,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4390,1,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4390,2,Splenic haematoma,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
4391,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4391,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4391,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4392,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4392,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4393,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4393,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4393,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4393,4,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
4393,5,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4393,6,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4393,7,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4393,8,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4393,9,Hypovolaemic shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4393,10,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4393,11,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4393,12,Peripheral circulatory failure,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4393,13,Tumour haemorrhage,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,Y
4393,14,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4394,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4394,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
4394,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4395,1,Headache,Headaches NEC,Headaches,Nerv,N
4395,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4395,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4395,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4396,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4397,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4397,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4398,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4399,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4400,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4400,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
4400,3,Rales,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
4401,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4402,1,Mucosal haemorrhage,Mucosal findings abnormal,General system disorders NEC,Genrl,N
4402,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4402,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4403,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4403,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4404,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
4405,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4406,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4406,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4407,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4407,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4408,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4408,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
4408,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4408,4,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4409,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4410,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4410,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4411,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4411,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4411,3,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4412,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4413,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4413,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4413,3,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4414,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4414,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4414,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4415,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4416,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4417,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4417,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4417,3,Gastrointestinal ulcer,"Gastrointestinal ulcers and perforation, site unspecified",Gastrointestinal ulceration and perforation,Gastr,N
4417,4,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4418,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4419,1,Gastric ulcer haemorrhage,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4420,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4420,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4421,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4422,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4422,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4423,1,Penile blister,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
4423,2,Penile necrosis,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
4423,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4423,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4424,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4424,2,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
4425,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4425,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4425,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4426,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4427,1,Pneumatosis intestinalis,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
4428,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4429,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4429,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4430,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4431,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
4432,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4432,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4432,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4433,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4434,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4435,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
4436,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4437,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4438,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4438,2,Product packaging confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4439,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4440,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4440,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4440,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4440,4,Septic embolus,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4440,5,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4441,1,Benign prostatic hyperplasia,Prostatic neoplasms and hypertrophy,Prostatic disorders (excl infections and inflammations),Repro,N
4441,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4441,3,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4442,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4443,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4444,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4445,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4445,2,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4445,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4445,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4446,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4446,2,Infarction,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4447,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4447,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4448,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4448,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4449,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4449,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4450,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4451,1,Cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4452,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4452,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4453,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
4453,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4454,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4454,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4454,3,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4455,1,Abnormal faeces,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
4455,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4455,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4455,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4456,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4457,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4458,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4459,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4459,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4459,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4459,4,Discoloured vomit,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4459,5,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4459,6,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4459,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4460,1,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
4461,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4461,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4461,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4462,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4462,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4463,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4463,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4464,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4465,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4466,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4467,1,Fracture nonunion,Fracture complications,Fractures,Musc,N
4468,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4469,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4470,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4470,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4470,3,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4471,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4472,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4472,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4472,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4472,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4473,1,Fracture nonunion,Fracture complications,Fractures,Musc,N
4474,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4475,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4475,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4476,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4476,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4477,1,Dose calculation error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4477,2,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4478,1,Fracture nonunion,Fracture complications,Fractures,Musc,N
4479,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4480,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
4480,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4480,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4480,4,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4481,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4482,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4482,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4483,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4483,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4484,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
4484,2,Headache,Headaches NEC,Headaches,Nerv,N
4484,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
4484,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4484,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4484,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4484,7,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4484,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4485,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4486,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4487,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4488,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4489,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4489,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4489,3,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4489,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4490,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4490,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4491,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4491,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4492,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4492,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4493,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4493,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4494,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4494,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4494,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4495,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4495,2,Foetal death,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
4495,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4496,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4496,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4497,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4497,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4498,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4498,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4499,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4499,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4500,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4500,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4500,3,Headache,Headaches NEC,Headaches,Nerv,N
4500,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4501,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4501,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4501,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4502,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4502,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4502,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4503,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4503,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4504,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4504,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
4505,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
4506,1,Gastritis erosive,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4506,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4507,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4507,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4508,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
4508,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
4508,3,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
4508,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4508,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4509,1,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4509,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4510,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4511,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4512,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4513,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4514,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4515,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4515,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4516,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4517,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4517,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4518,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4519,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4519,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4520,1,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
4520,2,Blood magnesium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
4520,3,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
4520,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4520,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4521,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4521,2,Haemorrhage urinary tract,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
4522,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
4522,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4522,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4523,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
4524,1,Headache,Headaches NEC,Headaches,Nerv,N
4524,2,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
4524,3,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4525,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4525,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4525,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4525,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4526,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4526,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4527,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4528,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4529,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4529,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4529,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4530,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4530,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4531,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4531,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
4532,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4533,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4534,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4535,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4536,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
4536,2,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4536,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4537,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4538,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4539,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4540,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4540,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4541,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4542,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4543,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4544,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4544,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4544,3,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4544,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4545,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
4545,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
4545,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4545,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4545,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4545,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4545,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4545,8,Pulmonary hilar enlargement,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
4545,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4545,10,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4546,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4547,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4548,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4548,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4548,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4548,4,Respiratory symptom,Respiratory signs and symptoms NEC,Respiratory tract signs and symptoms,Resp,N
4549,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4550,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
4550,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4550,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4550,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4550,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4550,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4551,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4552,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4553,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4554,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
4554,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4555,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4556,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4556,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4556,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4556,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4556,5,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4557,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4557,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
4557,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
4557,4,Delirium,Deliria,Deliria (incl confusion),Psych,N
4557,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4557,6,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4557,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4557,8,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4557,9,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
4557,10,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4557,11,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4558,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4559,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4560,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4560,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4560,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4560,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4560,5,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
4560,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4560,7,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4560,8,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4561,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4561,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
4562,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4563,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4563,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4564,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4564,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4564,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4565,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4565,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4566,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4566,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4567,1,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
4567,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
4568,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4568,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4568,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4568,4,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4568,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4569,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4570,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4571,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
4571,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4571,3,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4571,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4571,5,Flight of ideas,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4571,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4571,7,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4571,8,Language disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4571,9,Mania,Mood alterations with manic symptoms,Manic and bipolar mood disorders and disturbances,Psych,N
4571,10,Pressure of speech,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
4571,11,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
4571,12,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
4571,13,Thinking abnormal,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4571,14,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
4572,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4573,1,Cerebral ischaemia,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4573,2,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4573,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
4574,1,Cerebral ischaemia,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4574,2,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4575,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
4575,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4575,3,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4575,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4575,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4575,6,Flight of ideas,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4575,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4575,8,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4575,9,Language disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4575,10,Mania,Mood alterations with manic symptoms,Manic and bipolar mood disorders and disturbances,Psych,N
4575,11,Pressure of speech,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
4575,12,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
4575,13,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
4575,14,Thinking abnormal,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4575,15,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
4576,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4576,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4576,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4576,4,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
4576,5,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,Y
4577,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
4577,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
4577,3,Sunburn,Radiation injuries,Injuries by physical agents,Inj&P,N
4578,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4579,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
4579,2,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
4579,3,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4579,4,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4579,5,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
4579,6,Cerebral small vessel ischaemic disease,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
4579,7,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4579,8,Disorganised speech,Speech and language usage disturbances,Communication disorders and disturbances,Psych,N
4579,9,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4579,10,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4579,11,Flight of ideas,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4579,12,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
4579,13,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
4579,14,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4579,15,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4579,16,Mania,Mood alterations with manic symptoms,Manic and bipolar mood disorders and disturbances,Psych,N
4579,17,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4579,18,Pressure of speech,Speech articulation and rhythm disturbances,Communication disorders and disturbances,Psych,N
4579,19,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
4579,20,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
4579,21,Thinking abnormal,Thinking disturbances,Disturbances in thinking and perception,Psych,N
4579,22,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
4580,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4581,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4582,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4583,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4583,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4584,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4585,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4585,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4586,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4586,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4586,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4586,4,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
4586,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4586,6,Lactic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
4586,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4586,8,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4586,9,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4586,10,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4586,11,Transaminases abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4587,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4587,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4588,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4588,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4589,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4590,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4591,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
4591,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4591,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4591,4,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
4592,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4593,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4594,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4595,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4595,2,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4596,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4597,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4598,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4598,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4599,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4600,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4601,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4602,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4603,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4604,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4604,2,Middle cerebral artery stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4604,3,Paradoxical embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4604,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
4604,5,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4605,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4605,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4605,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4605,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4605,5,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4606,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4607,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4608,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4608,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4609,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4609,2,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4610,1,Apathy,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
4610,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
4610,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
4610,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4610,5,Hypersomnia,Narcolepsy and hypersomnia,Sleep disturbances (incl subtypes),Nerv,N
4610,6,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4611,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4611,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4612,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4613,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4613,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4614,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
4614,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4614,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4614,4,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4614,5,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4614,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4614,7,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4615,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4615,2,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4615,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4615,4,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4616,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4616,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4616,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4617,1,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4617,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4618,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4618,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4618,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4619,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
4619,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
4619,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4619,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4619,5,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
4620,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,Y
4620,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4621,1,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4621,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4622,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4622,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4623,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4624,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4625,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4626,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4627,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4627,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4627,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4627,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4627,5,Retinal vein occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4628,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4629,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4630,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4631,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4632,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
4632,2,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4632,3,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
4632,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4632,5,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4632,6,Hydronephrosis,Renal obstructive disorders,Renal disorders (excl nephropathies),Renal,N
4632,7,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4632,8,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4632,9,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4633,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
4634,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4635,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4635,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4635,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4636,1,Retinal vein occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4637,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4638,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4638,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4639,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
4640,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4640,2,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4640,3,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4641,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4641,2,Neovascular age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
4642,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
4642,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4643,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4643,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4644,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4644,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4644,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
4645,1,Eosinophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4645,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4645,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4645,4,Scratch,Skin injuries NEC,Injuries NEC,Inj&P,N
4646,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4647,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
4647,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4647,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4647,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4648,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4649,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4650,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4651,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4652,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4653,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4653,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4654,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
4655,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4656,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4656,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4657,1,Dieulafoy's vascular malformation,Gastrointestinal vascular malformations,Gastrointestinal vascular conditions,Gastr,N
4657,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4657,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4657,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4657,5,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4658,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4659,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4660,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4661,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4662,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4662,2,Ovarian cyst ruptured,Ovarian and fallopian tube cysts and neoplasms,Ovarian and fallopian tube disorders,Repro,N
4662,3,Pelvic haematoma,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
4663,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4663,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4664,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4664,2,Haemangioma of skin,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
4665,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4665,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4666,1,Haemorrhagic transformation stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4666,2,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4667,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
4667,2,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4667,3,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4667,4,Aortic arteriosclerosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4667,5,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
4667,6,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
4667,7,Change of bowel habit,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
4667,8,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
4667,9,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
4667,10,Congestive hepatopathy,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
4667,11,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4667,12,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
4667,13,Dilatation ventricular,Myocardial disorders NEC,Myocardial disorders,Card,N
4667,14,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4667,15,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4667,16,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
4667,17,Hepatic fibrosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
4667,18,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
4667,19,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
4667,20,Hepatorenal failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
4667,21,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4667,22,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4667,23,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
4667,24,Kidney fibrosis,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
4667,25,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4667,26,Mucosal dryness,Mucosal findings abnormal,General system disorders NEC,Genrl,N
4667,27,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4667,28,Nephrosclerosis,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4667,29,Ocular icterus,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
4667,30,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
4667,31,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4667,32,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
4667,33,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4667,34,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
4667,35,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
4667,36,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4667,37,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4667,38,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4667,39,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4667,40,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4668,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4669,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4669,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4670,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4671,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4671,2,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4671,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4671,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4671,5,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4672,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4672,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4673,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4673,2,Catheter site haemorrhage,Implant and catheter site reactions,Administration site reactions,Genrl,N
4673,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4673,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4673,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4673,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4674,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4674,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4675,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4675,2,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
4675,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4676,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4677,1,Penile haemorrhage,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
4678,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
4679,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4680,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4680,2,Hair texture abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
4681,1,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4682,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4683,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4683,2,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4684,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4685,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4685,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4686,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4687,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
4687,2,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4687,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4687,4,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4687,5,Headache,Headaches NEC,Headaches,Nerv,N
4687,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
4687,7,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4687,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4687,9,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
4687,10,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4687,11,Vertebrobasilar artery dissection,Central nervous system aneurysms and dissections,Central nervous system vascular disorders,Nerv,N
4688,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
4688,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4688,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4688,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4688,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4689,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4689,2,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4689,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
4689,4,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4689,5,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4689,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4689,7,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
4689,8,Oedematous kidney,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
4689,9,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4689,10,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4689,11,Renal tubular disorder,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4689,12,Renal tubular injury,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
4689,13,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
4689,14,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4690,1,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4691,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4691,2,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4692,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4693,1,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4694,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4695,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4695,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
4695,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4695,4,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
4696,1,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4697,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4697,2,Nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4697,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4698,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4698,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4698,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4698,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4698,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4699,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4700,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4700,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4701,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4701,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4701,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4702,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4703,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4704,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4704,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4705,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4705,2,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4705,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4705,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4705,5,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4705,6,Transplant rejection,Transplant rejections,Immune disorders NEC,Immun,N
4705,7,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4706,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4706,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4707,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4708,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4708,2,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
4709,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4710,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4710,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4711,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4711,2,Vaccination site bruising,Vaccination site reactions,Administration site reactions,Genrl,N
4712,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4713,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4714,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4714,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4715,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,Y
4716,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4717,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4717,2,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4718,1,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
4718,2,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4719,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4720,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4721,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4722,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
4722,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4723,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4723,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4723,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4723,4,Partial seizures,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
4724,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4725,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4726,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4727,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4727,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4728,1,Anticoagulant-related nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
4728,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4729,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4729,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4730,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4730,2,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4731,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4732,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4733,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4734,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4735,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4735,2,Scrotal pain,Scrotal disorders NEC,Penile and scrotal disorders (excl infections and inflammations),Repro,N
4736,1,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4737,1,Abdominal rigidity,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4737,2,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4737,3,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
4737,4,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4737,5,Scrotal pain,Scrotal disorders NEC,Penile and scrotal disorders (excl infections and inflammations),Repro,N
4737,6,Spermatic cord disorder,Testicular and epididymal disorders NEC,Testicular and epididymal disorders,Repro,N
4737,7,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4738,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4738,2,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4739,1,Primary amyloidosis,Amyloidoses,Immune disorders NEC,Immun,N
4740,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4740,2,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
4740,3,Polymyalgia rheumatica,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
4741,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4742,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4742,2,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
4742,3,Epidermal necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4742,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4742,5,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4742,6,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
4742,7,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4743,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4744,1,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4744,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4744,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4745,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
4745,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4745,3,Symptom recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4746,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4746,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4746,3,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4746,4,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
4747,1,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
4748,1,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4748,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4748,3,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4749,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4749,2,Catheter site thrombosis,Implant and catheter site reactions,Administration site reactions,Genrl,N
4749,3,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
4749,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4749,5,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4749,6,Iliac vein occlusion,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4750,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4750,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4751,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4751,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4752,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4753,1,Epidermal necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4753,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4753,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4754,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4754,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
4754,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4754,4,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4755,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4756,1,Product packaging difficult to open,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4756,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4757,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4757,2,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4757,3,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
4758,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
4758,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
4758,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4758,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4758,5,Symptom recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4759,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4759,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4759,3,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4759,4,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
4760,1,Spinal subdural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4761,1,Spinal subdural haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4762,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,Y
4762,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
4763,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4764,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4764,2,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4764,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4764,4,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
4764,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4764,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4765,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4766,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4766,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4766,3,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4767,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4767,2,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
4768,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4768,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4769,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4769,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
4769,3,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
4770,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4771,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4771,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4771,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4772,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4773,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4774,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
4775,1,Blood uric acid increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
4775,2,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
4776,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
4776,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4776,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4776,4,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
4776,5,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
4776,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4776,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4776,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4777,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4778,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4779,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4779,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4780,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4780,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4781,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4782,1,Device related sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
4782,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4782,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4782,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4783,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4784,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4785,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4785,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4786,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4787,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4787,2,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
4787,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4788,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4788,2,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4788,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4788,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4788,5,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
4788,6,Headache,Headaches NEC,Headaches,Nerv,N
4788,7,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
4788,8,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4788,9,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
4788,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4788,11,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4788,12,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4788,13,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4788,14,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4789,1,Catheter site haemorrhage,Implant and catheter site reactions,Administration site reactions,Genrl,N
4789,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
4789,3,Peritoneal dialysis complication,Dialysis related complications,Procedural related injuries and complications NEC,Inj&P,N
4790,1,Chest wall haematoma,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
4791,1,Cheilitis,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
4791,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
4791,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4791,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
4791,5,Oral mucosal eruption,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
4791,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4791,7,Pustule,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
4791,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4791,9,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
4791,10,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4791,11,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4792,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4793,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4793,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4793,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
4793,4,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
4793,5,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
4793,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4793,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4794,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4795,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4796,1,Antiphospholipid syndrome,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4796,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4796,3,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4796,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4797,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4797,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
4798,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4798,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4798,3,Ischaemia,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4799,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
4799,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4799,3,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
4799,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4800,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4800,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4801,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4801,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4801,3,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
4802,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4803,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4804,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4805,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4806,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4807,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4807,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4808,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4809,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4809,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4810,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
4810,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4810,3,Cerebral venous sinus thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
4810,4,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4810,5,Splenic vein thrombosis,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
4811,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4812,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4812,2,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4813,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4813,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4814,1,Aortic dissection,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
4814,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4814,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
4814,4,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
4814,5,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
4815,1,Cerebral venous sinus thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
4815,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4815,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4815,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
4816,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4816,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4817,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4818,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4819,1,Subcutaneous haematoma,Skin injuries NEC,Injuries NEC,Inj&P,N
4820,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4821,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4822,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4822,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4822,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4822,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4822,5,Transaminases abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4822,6,Weight fluctuation,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4823,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4823,2,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
4823,3,Upper airway obstruction,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
4824,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4824,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4824,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4824,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4824,5,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
4824,6,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
4825,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4825,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4826,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4827,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4828,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4829,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4829,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4830,1,Spinal fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
4831,1,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
4832,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4833,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4834,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4834,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
4834,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4834,4,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
4834,5,Headache,Headaches NEC,Headaches,Nerv,N
4834,6,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
4834,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4834,8,Intraocular pressure increased,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
4834,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4834,10,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4834,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4834,12,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4835,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4836,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4836,2,Product counterfeit,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4837,1,Thalamus haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4838,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4839,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4840,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4841,1,Abdominal wall haematoma,Abdominal wall conditions NEC,Abdominal hernias and other abdominal wall conditions,Gastr,N
4842,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4843,1,Blue toe syndrome,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4844,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4845,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4846,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4847,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4848,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4849,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4849,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4849,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4849,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4849,5,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
4850,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4850,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4851,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4851,2,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
4851,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4851,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4851,5,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4851,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4851,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4851,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4852,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4852,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4853,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4854,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4855,1,Haematinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4856,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4857,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4858,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4859,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4859,2,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4860,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4861,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4862,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4863,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4864,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4865,1,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4866,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4867,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4868,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4869,1,Epidural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4870,1,Congenital cardiovascular anomaly,Cardiovascular disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
4870,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4870,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4871,1,Chondroectodermal dysplasia,Non-site specific cartilage disorders congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
4871,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4871,3,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
4871,4,Paranasal sinus hypoplasia,Nasal disorders congenital,Respiratory disorders congenital,Cong,N
4872,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4873,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4874,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4874,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4874,3,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
4874,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4874,5,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
4874,6,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4875,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4876,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4876,2,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
4876,3,Teratogenicity,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
4877,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4877,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4878,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4879,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
4879,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4880,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4881,1,Adrenal haemorrhage,Adrenal gland disorders NEC,Adrenal gland disorders,Endo,N
4881,2,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
4882,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4883,1,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4884,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4884,2,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
4885,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4886,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4887,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4887,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4888,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4888,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4889,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4890,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4891,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4892,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4892,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4892,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4892,4,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4893,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4893,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4894,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4895,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4896,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4896,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4896,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4896,4,Pulse abnormal,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
4896,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4897,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4898,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
4899,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4900,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4900,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4900,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4900,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4900,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4901,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4901,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4901,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4902,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4902,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4903,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4903,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4904,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4904,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4905,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4905,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4906,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4906,2,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4906,3,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4906,4,Colon cancer,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
4906,5,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4906,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4907,1,Basal ganglia haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4907,2,Headache,Headaches NEC,Headaches,Nerv,N
4907,3,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4908,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4908,2,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
4908,3,Headache,Headaches NEC,Headaches,Nerv,N
4908,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4908,5,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4908,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4908,7,Superior vena cava syndrome,Site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
4908,8,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4908,9,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
4908,10,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4909,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4909,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4910,1,Choroidal haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
4910,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4910,3,Hyphaema,Eye injuries NEC,Injuries NEC,Inj&P,N
4910,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4910,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
4911,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4912,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4912,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4912,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4913,1,Abdominal adhesions,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
4913,2,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4913,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4913,4,Encapsulating peritoneal sclerosis,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
4913,5,Gastric dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
4913,6,Gastrointestinal wall thickening,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4913,7,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
4913,8,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4913,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4913,10,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4913,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4914,1,Retroplacental haematoma,Haemorrhagic complications of pregnancy,Maternal complications of pregnancy,Preg,N
4915,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4916,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4917,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4918,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
4918,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4919,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4919,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4920,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4921,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4922,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
4922,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4922,3,Encapsulating peritoneal sclerosis,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
4922,4,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4922,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
4922,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4923,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4923,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
4924,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4924,2,Implant site haematoma,Implant and catheter site reactions,Administration site reactions,Genrl,N
4924,3,Vascular anastomosis,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
4924,4,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4925,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4926,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4926,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4927,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4927,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4928,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4928,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4929,1,Herbal interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4929,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4930,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4930,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4931,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4931,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4932,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
4933,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4933,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4934,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4935,1,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
4935,2,Pupil fixed,Pupil disorders,Ocular neuromuscular disorders,Eye,N
4935,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
4936,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4936,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4937,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4938,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4938,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4939,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4940,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4941,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4942,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4942,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
4943,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4944,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4944,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4945,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4946,1,Acute oesophageal mucosal lesion,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
4946,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4946,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4946,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4946,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4946,6,Oesophageal intramural haematoma,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4946,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4947,1,Brown-Sequard syndrome,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
4947,2,Extensor plantar response,Abnormal reflexes,Neurological disorders NEC,Nerv,N
4947,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
4947,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4947,5,Hyporeflexia,Abnormal reflexes,Neurological disorders NEC,Nerv,N
4947,6,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4947,7,Paraparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
4947,8,Spinal cord haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4947,9,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
4948,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4949,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4950,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4951,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4951,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4952,1,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4952,2,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
4952,3,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
4952,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
4953,1,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
4954,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4955,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4956,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
4956,2,Genitourinary symptom,Genital and urinary tract disorders NEC,Genitourinary tract disorders NEC,Renal,N
4957,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4958,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
4958,2,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,Y
4958,3,Aortic rupture,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
4958,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
4958,5,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
4958,6,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
4958,7,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4958,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4958,9,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
4958,10,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4958,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
4958,12,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4959,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4960,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4961,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4962,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4963,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4963,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
4963,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
4963,4,Hypovolaemia,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
4963,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4964,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4965,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4966,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4967,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4967,2,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
4967,3,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4967,4,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
4967,5,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4967,6,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
4967,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4967,8,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
4967,9,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4967,10,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
4967,11,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
4967,12,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
4967,13,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
4967,14,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
4967,15,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
4967,16,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4967,17,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4967,18,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4967,19,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4967,20,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4967,21,Steroid dependence,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4967,22,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
4967,23,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
4968,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
4969,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4970,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4971,1,Bone erosion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
4972,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4973,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4973,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4974,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4974,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4975,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4975,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4976,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
4976,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4976,3,Orthostatic hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4977,1,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
4978,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4979,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4980,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4981,1,Acquired haemophilia,Coagulation factor deficiencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4982,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4982,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4983,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
4983,2,Stillbirth,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
4984,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4985,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4986,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4987,1,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4987,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4987,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
4988,1,Haematoma muscle,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4988,2,Headache,Headaches NEC,Headaches,Nerv,N
4988,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
4988,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4988,5,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
4988,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4988,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4988,8,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4989,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4990,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4991,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4992,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
4992,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4993,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4993,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4994,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
4995,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
4996,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4997,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4997,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4998,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
4999,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5000,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5001,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5002,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5003,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5004,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5004,2,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5004,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5005,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5006,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5007,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5008,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5009,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
5009,2,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5009,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
5010,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5011,1,Abortion induced,Induced abortions,Obstetric and gynaecological therapeutic procedures,Surg,N
5011,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
5011,3,Cardiac monitoring,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
5011,4,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5011,5,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5012,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5013,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5014,1,Antiphospholipid syndrome,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
5015,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5015,2,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
5015,3,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5016,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5017,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5018,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5019,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5020,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5020,2,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5020,3,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
5020,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
5020,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5020,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5020,7,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5021,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5022,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5023,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5024,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5025,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5026,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5026,2,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
5026,3,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
5026,4,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
5026,5,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5026,6,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
5026,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5026,8,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
5026,9,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5026,10,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5026,11,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
5026,12,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5026,13,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5026,14,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5026,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5026,16,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5026,17,Steroid dependence,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5026,18,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
5026,19,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
5027,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5028,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5029,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5030,1,Arteriovenous fistula,Vascular malformations and acquired anomalies,Vascular disorders NEC,Vasc,N
5030,2,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5031,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5032,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5033,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5033,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5034,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5035,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5036,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5037,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5038,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5039,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5040,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5041,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5042,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5042,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5043,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5044,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5044,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5045,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
5045,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5046,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5047,1,Cerebral cyst haemorrhage,Nervous system cysts and polyps,Nervous system neoplasms benign,Nerv,N
5048,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5049,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5050,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5051,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5052,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5053,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5053,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5053,3,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
5054,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5054,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5054,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5055,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
5055,2,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
5055,3,Blood iron decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
5055,4,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
5055,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5055,6,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
5055,7,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
5055,8,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
5055,9,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
5055,10,Heel fat pad syndrome,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
5055,11,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5055,12,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
5055,13,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
5055,14,Plantar fasciitis,Musculoskeletal and connective tissue infections and inflammations NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
5055,15,Poor peripheral circulation,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
5055,16,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
5055,17,Rheumatic disorder,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
5055,18,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5055,19,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5056,1,Depression suicidal,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
5057,1,Depression suicidal,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
5058,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5059,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5060,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5061,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5062,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5063,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5064,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5065,1,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
5066,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
5067,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5068,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
5069,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5070,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
5070,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5071,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
5072,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5073,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5074,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5075,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5076,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5077,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5078,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5078,2,Pulmonary alveolar haemorrhage,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
5079,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
5080,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5081,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5082,1,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5083,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5084,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
5084,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
5085,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5086,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5086,2,Pulmonary alveolar haemorrhage,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
5087,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5087,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5088,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5089,1,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5090,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
5091,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5092,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5092,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
5092,3,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
5092,4,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
5092,5,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
5093,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5093,2,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
5094,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5094,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
5094,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
5094,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5094,5,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
5094,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
5095,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5095,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
5095,3,Product after taste,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
5095,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
5095,5,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5096,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5097,1,Dystrophic calcification,Trophic disorders,Tissue disorders NEC,Genrl,N
5098,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5099,1,Headache,Headaches NEC,Headaches,Nerv,N
5100,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5101,1,Haemothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
5102,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
5103,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5104,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5104,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5105,1,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
5106,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5107,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
5108,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5109,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5110,1,Anticoagulation drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
5111,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5112,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5113,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,Y
5114,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5115,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5116,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5117,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5117,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
5118,1,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5118,2,Retinal artery occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
5119,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
5120,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5121,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5122,1,Calciphylaxis,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
5122,2,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5123,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5124,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5125,1,Lip haematoma,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
5126,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5126,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5126,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
5126,4,Pyelonephritis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
5126,5,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5127,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5128,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5129,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5130,1,Blood viscosity decreased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
5130,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5130,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5130,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5131,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5132,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
5133,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5134,1,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
5134,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5135,1,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
5135,2,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
5136,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
5136,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5136,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
5136,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5137,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5138,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5139,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5139,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
5140,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5141,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
5142,1,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
5142,2,Iris haemorrhage,Iris and ciliary body bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
5142,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5142,4,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5143,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
5143,2,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
5143,3,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
5143,4,Pulmonary toxicity,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
5144,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5144,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
5144,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5145,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
5145,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5145,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5146,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5147,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5147,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5147,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5148,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5148,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5148,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
5148,4,Subarachnoid haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5149,1,Craniocerebral injury,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5150,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5150,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5150,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5151,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
5152,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5153,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5153,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5153,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5154,1,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5154,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5155,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5155,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5155,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5155,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5155,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
5156,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5156,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5156,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5157,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
5157,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
5157,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
5157,4,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
5157,5,Escherichia urinary tract infection,Escherichia infections,Bacterial infectious disorders,Infec,N
5157,6,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
5157,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
5157,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5158,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5159,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5159,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5159,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5160,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5161,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5161,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5162,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5162,2,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
5163,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5163,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
5163,3,Foetal warfarin syndrome,Chemically-induced congenital syndromes,Congenital and hereditary disorders NEC,Cong,N
5163,4,Low birth weight baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
5163,5,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
5164,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5165,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5165,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5166,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
5167,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5168,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
5168,2,Headache,Headaches NEC,Headaches,Nerv,N
5168,3,Migraine,Migraine headaches,Headaches,Nerv,N
5169,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5169,2,Parietal lobe stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5169,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5170,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5170,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5171,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5171,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5172,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
5173,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
5174,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5174,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5175,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5176,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5177,1,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
5178,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5179,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5180,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
5181,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
5182,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
5182,2,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
5183,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
5184,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5185,1,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5186,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
5186,2,Lower gastrointestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
5186,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
